

Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior

Rhonda P. Patrick¹ and Bruce N. Ames¹

Nutrition and Metabolism Center, Children's Hospital Oakland Research Institute, Oakland, California, USA

ABSTRACT Serotonin regulates a wide variety of brain functions and behaviors. Here, we synthesize previous findings that serotonin regulates executive function, sensory gating, and social behavior and that attention deficit hyperactivity disorder, bipolar disorder, schizophrenia, and impulsive behavior all share in common defects in these functions. It has remained unclear why supplementation with omega-3 fatty acids and vitamin D improve cognitive function and behavior in these brain disorders. Here, we propose mechanisms by which serotonin synthesis, release, and function in the brain are modulated by vitamin D and the 2 marine omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Brain serotonin is synthesized from tryptophan by tryptophan hydroxylase 2, which is transcriptionally activated by vitamin D hormone. Inadequate levels of vitamin D (~70% of the population) and omega-3 fatty acids are common, suggesting that brain serotonin synthesis is not optimal. We propose mechanisms by which EPA increases serotonin release from presynaptic neurons by reducing E₂ series prostaglandins and DHA influences serotonin receptor action by increasing cell membrane fluidity in postsynaptic neurons. We propose a model whereby insufficient levels of vitamin D, EPA, or DHA, in combination with genetic factors and at key periods during development, would lead to dysfunctional serotonin activation and function and may be one underlying mechanism that contributes to neuropsychiatric disorders and depression. This model suggests that optimizing vitamin D and marine omega-3 fatty acid intake may help prevent and modulate the severity of brain dysfunction.—Patrick, R. P., Ames, B. N. Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior. *FASEB J.* 29, 2207–2222 (2015). www.fasebj.org

Key Words: eicosapentaenoic acid • docosahexaenoic acid • mental illness

Abbreviations: 5-HIAA, 5-hydroxy-indole acetic acid; 5-HT, serotonin; 25(OH)D₃, 25-hydroxyvitamin D; ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorders; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; IDO, indoleamine 2,3-dioxygenase; TPH, tryptophan hydroxylase; TPH1, tryptophan hydroxylase 1; TPH2, tryptophan hydroxylase 2; VDRE, vitamin D response element

“The rapid progress true science now makes, occasions my regretting sometimes that I was born too soon. It is impossible to imagine the height to which may be carried, in a thousand years, the power of man over matter. We may, perhaps, deprive large masses of their gravity, and give them absolute levity, for the sake of easy transport. Agriculture may by sure means be prevented or cured, (not excepting even that of old age,) and our lives lengthened at pleasure, even beyond the antediluvian standard. Oh that moral science were in as fair a way of improvement, that men would cease to be wolves to one another, and that human beings would at length learn what they now improperly call humanity.”

– Benjamin Franklin, letter to Joseph Priestley, 1780

SEROTONIN PLAYS A CRITICAL role in brain function as a neurotransmitter, hormone, and brain morphogen (1). Serotonin is concentrated in discrete brain regions known to regulate social cognition and decision-making that have been collectively called “the social brain” (2–4). There is an abundance of evidence linking serotonin to social behavior (5, 6). For example, polymorphisms in the serotonin transporter gene have been linked to social behavioral defects including aggression, impulsivity, anxiety, psychopathology, and personality disorder (7–11). Experimentally lowering brain serotonin levels in normal people has a wide range of behavioral consequences: impulsive behavior, impaired learning and memory, poor long-term planning, inability to resist short-term gratification, and social behavioral deficits characterized by impulse aggression or lack of altruism (5, 12–14). Because social behavior is disrupted in many brain disorders, such as autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), bipolar disorder, schizophrenia, impulsive behavior disorder, depression, and anxiety, understanding the biologic mechanisms that regulate the serotonin pathway are important for understanding how social cognition and decision-making become dysfunctional in these disorders.

Despite the wealth of data that links serotonin to social behavior, specific factors that make an individual more susceptible to social-cognitive dysfunction and mental

¹ Correspondence: Children's Hospital Oakland Research Institute, 5700 M.L. King Jr. Way, Oakland, CA 94609, USA. E-mail: rpatrick@chori.org (R.P.P.), and bames@chori.org (B.N.A.)
doi: 10.1096/fj.14-268342

illness remain unclear. One challenge in this field of research is the complexity of interactions that manifest as a given disorder. Neuropsychiatric disorders are multifactorial and are likely influenced by a complex interaction between genetics, nutrition, and environment (15). There has been significant progress in the identification of gene variations associated with psychiatric disorders and some have shared genetic etiology (16). What is less understood is how nutritional deficiencies may interact with genetic pathways, such as the serotonin pathway, that are important for brain development, social cognition, and decision-making, and how the gene-environment interactions may trigger mental illness. Cognitive functioning involves billions of neurons working with numerous biochemical pathways and associated enzymes. Many of these enzymes require micronutrients, essential vitamins, and minerals as cofactors for optimal function. Thus, one expects that suboptimal function caused by micronutrient inadequacies could adversely affect the functions of proteins and enzymes involved in brain function. Multiple factors including micronutrient inadequacies, exercise, inflammation, and stress have all been shown to influence the serotonin pathway, as we will discuss here, and, consequently, affect social behavior (schematic representation of serotonin pathway illustrated in Fig. 1) (17–21). In a previous paper (part 1 of this series), we provided evidence for a biologic mechanism by which vitamin D hormone regulates serotonin synthesis in a tissue-specific manner and how aberrant serotonin production during fetal and neonatal development may play a central causal role in ASD (22).

Here, we assemble evidence from the literature that serotonin regulates executive function, impulsivity, sensory gating, and social behavior and propose that ASD, ADHD, bipolar disorder, schizophrenia, and impulsive behavior all share defects in these functions because of dysfunction in the serotonin pathway. We build on our previous findings on how vitamin D hormone is a key regulator of brain serotonin synthesis through tryptophan hydroxylase 2 (*TPH2*), which contains a vitamin D response element (VDRE) consistent with activation and how this relates to psychiatric disorders (22). We propose mechanisms by which the marine omega-3 fatty acids eicosapentaenoic acid (EPA) increases serotonin release from presynaptic neurons by reducing E2 series prostaglandins and docosahexaenoic acid (DHA) influences serotonin action by increasing membrane fluidity and thus serotonin receptor accessibility in postsynaptic neurons. Because vitamin D insufficiency and low dietary intake of omega-3 fatty acids are very common, we propose that suboptimal intake of these micronutrients contribute to dysfunction of the serotonin pathway, and, in combination with genetic factors, exacerbate dysfunction in the serotonin system, resulting in defects in executive function, impulse control, sensory gating, and prosocial behavior, and precipitate neuropsychiatric disorders. These brain disorders have a higher male incidence, which we suggest is because of a protective effect of estrogen, resulting in an increase in brain serotonin synthesis in females. Finally, we suggest that supplementation with vitamin D and omega-3 fatty acids may aid in the prevention of mental illness and/or help modulate the severity of brain dysfunction.

ROLE OF SEROTONIN IN NEUROPSYCHIATRIC ILLNESS

Serotonin regulates executive function and sensory gating

Executive function is modulated by serotonin, and it is essential for planning and decision-making; the latter of these actions involves weighing the expected gains, losses, and probabilities of each of these outcomes (19, 23). Brain serotonin levels have been experimentally lowered by administering branch-chain amino acids, which strongly outcompete tryptophan for transport across the blood-brain barrier and cause serotonin levels to plummet (hereafter referred to as acute tryptophan depletion) (23). Acute tryptophan depletion in healthy volunteers, which lowers brain serotonin levels, compromises the decision-making process by altering the ability to distinguish the magnitude of differences between immediate *versus*, long-term rewards (19). Tryptophan depletion also increases the tendency to choose the less probable outcome, similarly to what happens in amphetamine drug users and individuals with damage to the prefrontal cortex, which compromises executive function (24). Another integral part of decision-making is the ability to abstain from short-term gratification to benefit in the long term. Depleting serotonin in normal individuals shifts their behavior toward lack of impulse control and short-term gratification at the expense of long-term benefits (13, 25–27). Tryptophan depletion results in enhanced activity in the ventral striatum, which is the part of the brain associated with short-term decision-making (28). In contrast, supplementation with tryptophan causes activation of the dorsal striatum, which is responsible for long-term decision-making (28). Thus, it appears that decision-making and impulsive choices are both controlled by serotonin.

Sensory gating, which is the ability of the brain to filter out extraneous sensory inputs, also depends on serotonin levels. Defects in sensory gating cause a sensory overload of irrelevant information resulting in cognitive fragmentation, which shares comorbidity with numerous psychopathological disorders (21–26). Acute tryptophan depletion in normal individuals results in impaired sensory gating, thus suggesting that serotonin plays an important role in this process (29, 30). Defects in sensory gating may also affect executive function and decision-making. In general, the overall data support the concept that low serotonin levels lead to impairments in executive function and sensory gating.

Serotonin regulates social behavior and impulsivity

Serotonin plays an important role in inhibiting impulsive aggression toward self, including suicide, and aggression toward others (5, 31). Depleting brain serotonin levels in normal individuals results in a shift away from cooperative behavior in favor of short-term gain and results in antisocial behavior, increased uncontrolled aggressive behavior, feelings of anger, quarrelsome behavior, and self-injury (5, 20, 32–35). In adolescents with ADHD, depleting brain




Figure 1. Metabolic pathways of tryptophan. Stress and inflammation activate the enzymes indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO), which metabolize tryptophan to kynurenine and shunt it away from transport into the brain. Alternatively, tryptophan can be metabolized by the enzyme tryptophan hydroxylase 1 (TPH1), which uses tetrahydrobiopterin (BH4) and iron as cofactors, to produce 5-hydroxytryptophan (5HTP). 5HTP is metabolized by the enzyme aromatic L-amino acid decarboxylase (AAAD), which uses pyridoxal 5-phosphate (P5P) as a cofactor, to produce 5HT. 5HT is metabolized by the enzyme *N*-acetyl transferase (AANAT) to produce the sleep hormone, melatonin. To produce serotonin (5HT) in the brain, tryptophan must first be transported across the blood-brain barrier. This transport depends on the ratio of tryptophan to branch-chain amino acids, which strongly outcompete tryptophan for transport across the blood-brain barrier. Exercise alleviates this competition by increasing the uptake of branch-chain amino acids into muscle, thus raising tryptophan availability to the brain. Inside the brain, tryptophan is metabolized by the rate-limiting enzyme, tryptophan hydroxylase 2 (TPH2), to produce 5HTP in the brain. 5HTP is metabolized by AAAD to produce 5HT in the brain. 5HT is metabolized by the enzyme monoamine oxidase (MAO) to produce the inactive serotonin metabolite 5-hydroxyindoleacetic acid (5HIAA).

serotonin levels increased aggressive behavior (36). Depleting brain serotonin levels has also been shown to cause loss of inhibitory behavior against adverse consequences, which is linked to recidivism (5, 12, 14, 33). In contrast, acutely enhancing brain levels of serotonin causes people to become more averse to harming others, suggesting that serotonin may play a role in moral behavior (20). Tryptophan supplementation has been shown to decrease social anxiety and quarrelsome behavior in normal individuals and in irritable individuals and may therefore improve overall social behavior (37–40). Additionally, tryptophan supplementation in young boys with disruptive behavior decreased impulsivity and increased social cooperation (41). Furthermore, tryptophan supplementation

in schizophrenics can reduce aggression and the need for antipsychotics (42, 43). These studies support a causal role for serotonin in regulating social behavior.

In nonhuman primates, low brain serotonin also leads to severe aggressive behavior and lack of impulse control (44). In mice, dietary tryptophan depletion increases killing behavior that is ameliorated by boosting brain serotonin levels (45, 46). Mutant mice that have a nonfunctional or deleted *tph2*, and thus have no serotonin synthesis in the brain, display exaggerated aggressive behavior and compulsive behavior compared with control mice (47–49). These data provide evidence that serotonin deficiency in the brain leads to magnified aggression.

Polymorphisms in serotonin-related genes are associated with mental illness

ASD, ADHD, bipolar disorder, schizophrenia, and impulsive behavior disorders have significant overlap because they all exhibit impairments in executive function, sensory gating, and social behavior. These impairments are characterized by a plethora of phenotypes including poor long-term planning skills, impulsivity, poor attention switching, emotional dysregulation, impaired sensory gating, poor social skills, impulse aggression toward self and others, and depression (50–58). Because serotonin plays a key role in regulating many of these executive and behavioral functions, aberrant serotonin signaling is likely to be a unifying underlying cause common to these psychopathologic disorders. Indeed, brain serotonin has been shown to be low in ASD, ADHD, bipolar disorder, schizophrenia, and impulsive behavior disorders (22, 59–61). The concentration of the serotonin metabolite 5-hydroxy-indole acetic acid (5-HIAA) in cerebrospinal fluid is a biomarker for low brain serotonin levels. Low 5-HIAA levels are associated with detrimental behaviors such as aggression, violent suicide, impulsive murder, and recidivism of murder and have also been found in individuals with depression (62–68).

Polymorphisms in the *TPH2* gene and other serotonin-related genes provide additional support that aberrant brain levels of serotonin are associated with increased susceptibility to ASD, ADHD, bipolar disorder, schizophrenia, and impulsive behavior, including aggression toward self and others (22, 69–75). These polymorphisms are also associated with aggression, depression, and anxiety, which are all common psychologic abnormalities in these psychiatric disorders (76–78). Suicide is strongly linked to impulsive behavior and polymorphisms in tryptophan hydroxylase, and other serotonin-related pathways have been linked to increased suicide attempts (79, 80). In a recent study, 58% of suicide attempters were vitamin D deficient, their levels of vitamin D being significantly lower than those in healthy individuals and patients with depression, but without suicidality (81). In line with this, lower duration of daily sunshine has also been linked to higher suicide frequency independent of season (82, 83).

THE ROLE OF VITAMIN D IN NEUROPSYCHIATRIC ILLNESS

Vitamin D regulates serotonin

Vitamin D is first converted to 25-hydroxyvitamin D [25(OH)D₃], which is the major stable circulating form of vitamin D, and then to the biologically active steroid hormone 1,25-dihydroxyvitamin D (84). We recently proposed an underlying mechanism that describes how vitamin D hormone, which appears to control >900 genes, is a key regulator of brain serotonin synthesis through *TPH2*, which contains a VDRE consistent with activation (22, 85). We identified 2 distinct VDREs present in the regulatory regions of both *TPH2* and *TPH1*, the 2 genes responsible for the conversion of tryptophan into serotonin in the brain vs. other tissues, respectively (22). We proposed that the VDREs would respond to vitamin D

hormone in an inverse mode, with *TPH2* being transcriptionally activated in the brain and *TPH1* repressed in tissues outside of the blood-brain barrier (22). This proposal was based on evidence that the VDRE sequence alone can determine whether vitamin D hormone will activate or repress gene transcription (86). New biochemical evidence validates our proposal by showing that vitamin D hormone activates *TPH2* expression in cultured neuronal cells (M. Haussler, personal communication, 7/19/2014; see Note added in proof).

Vitamin D sufficiency

The precise blood level of 25(OH)D₃ that is defined as vitamin D deficiency remains somewhat controversial. Based on the classic function of vitamin D, which is to maintain bone homeostasis, vitamin D deficiency has been defined by the Institute of Medicine as 25(OH)D₃ serum concentrations <20 ng/ml (87). The current guidelines for vitamin D sufficiency have been suggested to be >30 ng/ml (87).

According to the U.S. National Health and Nutrition Examination Survey, vitamin D sufficiency (30–60 ng/ml) decreased between 1994 and 2004 from ~60% to 30% in whites, from 10% to 5% in African Americans, and from 24% to 6% in Latinos, indicating that more than half of the US population has insufficient levels of this critical vitamin D hormone (88, 89). Currently, ~70% of adults and 67% of children aged 1–11 y in the United States do not have adequate levels of vitamin D even when fortification and supplementation are considered (89–91). Epidermal synthesis of vitamin D requires the action of UVB radiation emitted from the sun; however, the use of sunscreen and also a high level of melanin, the brown pigment found in skin, block UVB radiation, thus impairing the ability of the skin to synthesize vitamin D (84, 92, 93). In addition, living at Northern latitudes decreases skin exposure to UVB (84). A modest amount of vitamin D can be obtained through dietary sources, such as seafood, which is its relatively richest dietary source (94). Some foods have been fortified with vitamin D, including milk (100 IU per 8 oz) and orange juice (100 IU per 8 oz), but these levels are not sufficient to achieve an adequate vitamin D status of 30 ng/ml. Furthermore, dairy products are a poor choice for fortification for the ~50 million Americans who are lactose intolerant, including 75% of African Americans (95).

Vitamin D may modify severity of brain dysfunction

There may be a very important interaction between genetics and vitamin D hormone that could play a role in modulating the severity of mental illness. Individuals with polymorphisms in serotonin-related genes are already predisposed to dysregulation in the synthesis or metabolism of serotonin; thus, any additional decrease in serotonin synthesis as a consequence of inadequate levels of vitamin D may exacerbate defects in executive function, sensory gating, and impulsive behavior. Low 25(OH)D₃ serum concentrations have been shown to be associated with an elevated risk for ASD, ADHD, bipolar disorder, schizophrenia, antisocial behavior, and impulsive behavior (22, 96–101). There appears to be an interaction between

polymorphisms in serotonin-related genes and season of birth: individuals with bipolar disorder or schizophrenia who also have polymorphisms in the *TPH* gene or the gene that encodes the serotonin transporter have an increased risk of mental illness if they were born in winter/spring months (102). The interaction between vitamin D deficiency and defects in serotonin-related genes has also been demonstrated in mice: mice that already have reduced serotonin synthesis caused by a polymorphism in their *TPH2* gene are very sensitive to vitamin D deficiency in adulthood and as a result have profound defects in cognitive function and behavior when vitamin D is restricted (103, 104). Presumably, these mice have more pronounced defects in behavior because of further dampening of serotonin synthesis as a consequence of vitamin D deficiency. These studies highlight the role that vitamin D hormone plays in modulating severity of brain dysfunction in combination with genetic factors affecting brain serotonin levels.

Timing of vitamin D deficiency may exacerbate brain dysfunction

In addition to genetic factors, the timing of vitamin D deficiency and stage of development in which it occurs affects the severity of executive function, sensory gating, and social behavior dysfunction. Gestational vitamin D deficiency in rats leads to later impairments in latent inhibition (which is related to sensory gating), attention processing, and impulsive behavior (105, 106). Consistent with these results, mutant mice lacking a functional vitamin D receptor have defects in sensory gating and abnormal social behavior, including social neglect and impulsive behavior (107, 108). However, when vitamin D is restricted only during adulthood, the behavioral abnormalities, including impulsive behavior and impaired attention processing, are more subtle than the effects of vitamin D deficiency throughout life (107–109). These subtle effects of vitamin D deficiency during adulthood are in contrast with the more severe behavioral effects observed in mice that are already predisposed to low serotonin synthesis (104). Thus, the severity of behavioral abnormalities in response to low vitamin D are more pronounced when deficiency occurs during development but are also exacerbated by genetic factors that also affect the serotonin system.

Insufficient vitamin D during early development can precipitate social cognition, decision-making, and brain morphology defects that share similarity with many brain disorders. This may in part be because of the important role vitamin D and serotonin both have on the structure and wiring of the brain (110, 111). In rats, gestational vitamin D deficiency leads to a 200% increase in lateral ventricle volume, a slightly lower neocortical width, increased cell proliferation, decreased differentiation, and a decrease in neurotrophic factors (112, 113). In humans, gestational vitamin D deficiency has been shown to cause an increase in neonatal ventricle size by as much as 28% (114). Enlargement of cerebral lateral ventricles is known to be associated with ASD, ADHD, and schizophrenia (115). It is plausible if this aberrant brain morphology is assumed to play a role in the etiology of these brain disorders, perhaps this same ventricular enlargement, when caused by early gestational vitamin D deficiency, may also

precipitate those same illnesses in the presence of the correct genetic-environmental background.

There is significant evidence that low vitamin D levels during gestational and neonatal development are a risk factor for schizophrenia and psychosis, in some cases raising the risk by 6-fold (97, 98, 116–119). Furthermore, the absence of vitamin D supplementation during pregnancy is associated with an increased risk of schizophrenia in male children (120). Low vitamin D levels have been associated with an increased risk of psychotic experiences in both childhood and adolescence (121, 122). A meta-analysis found schizophrenia prevalence rates increased significantly with increased latitude; however, lighter skin color, a factor improving vitamin D status, and high intake of fish were both associated with protection against schizophrenia (99). These data suggest that vitamin D may play an important role in shaping the structure of the developing brain and decreasing psychosis and schizophrenia.

Vitamin D supplementation: a simple solution?

Supplementation with vitamin D during early brain development may be able to decrease the risk of neuropsychiatric disorders and supplementation later in life may improve brain dysfunction. This may be partially mediated through the ability of vitamin D to activate *TPH2* and thus increase serotonin synthesis (22) (M. Haussler, personal communication, 7/19/2014). Low levels of vitamin D are common in ASD, ADHD, bipolar disorder, schizophrenia, and impulsive behavior (22, 81, 96, 122–125). For this reason, many individuals at risk or already diagnosed with any of these disorders would benefit by a vitamin D supplement. Indeed, vitamin D supplementation during the first year of life decreased the incidence of schizophrenia by 77% (120). This is particularly relevant because there is a wide range of vitamin D insufficiency among pregnant women (up to 91%) in the United States. This level of insufficiency varies according to which state people live in, perhaps because of differences in sun exposure (126). Approximately 50% of mothers taking prenatal vitamins and their neonates had insufficient levels of vitamin D, whereas supplementation with 4000 IU/d, which is the upper tolerable intake, was safe and most effective in achieving adequate vitamin D concentrations without toxicity (127, 128). Vitamin D supplementation has also been shown to improve inattention, hyperactivity, and impulsivity in children and adults with ADHD (129, 130). Given the widespread vitamin D deficiency, particular in those with brain dysfunction, these data suggest that a vitamin D supplement that is 4000 IU may be able to eliminate vitamin D deficiency and help reduce psychiatric disease risk and improve brain function. More clinical studies investigating this will shed light.

OMEGA-3 FATTY ACIDS REGULATE SEROTONIN FUNCTION

Omega-3 fatty acids affect behavior

Long chain marine omega-3 fatty acids in the brain consist primarily of the C22 *n*-3 DHA with some C20 *n*-3 EPA (131).

Blood concentrations of EPA and DHA have been found to be low in individuals with a wide range of psychiatric illnesses including ASD, ADHD, bipolar disorder, schizophrenia, suicide attempters, and other impulsive behavior; supplementation has been shown to have a beneficial role in modifying the severity of symptoms (22, 132–136). Schizophrenics have significantly lower DHA levels in the orbitofrontal cortex region of the brain, where serotonin is concentrated, compared with normal individuals (137). Epidemiologic studies suggest that ω -3 deficiency may be a risk factor for bipolar disorders: plasma DHA is significantly decreased in patients with bipolar disorder (135). Suicidal ideation is common in individuals with bipolar disorder and depression and has been linked to both low omega-3 and low serotonin in the brain (138, 139). Randomized controlled trials have found that supplementation with several grams of EPA and DHA improved depression, suicidal thoughts, and behaviors (132, 140). Supplementation with omega-3 from fish oil was shown to improve cognitive function, including language skills, concentration, motor skills, schizophrenic symptoms, and aggressive and impulsive behavior (132, 141). Intervention studies have shown that supplementation with omega-3 fatty acids improved aggression, anger, hostility, antisocial behavior, anxiety, and impulsivity in normal school children, juvenile delinquents, adolescents, prison inmate populations, and substance abuse users (142, 143). Although many recent meta-analyses show a clear benefit for omega-3 fatty acids in the treatment of depression, there is some heterogeneity between clinical trials (144–149). Some plausible explanations for inconsistent results include genetic variation, omega-3 fatty acid from diet, and different EPA and DHA doses in various formulations, as EPA appears to play a more important role (150, 151). A large clinical trial measuring omega-3 fatty acid concentrations in red blood cells and testing multiple doses of EPA and DHA compared with placebo should help shed light.

EPA regulates serotonin release

We propose that one important mechanism by which omega-3 fatty acids modulate serotonin function is through regulation of serotonin release in the presynaptic neuron (Fig. 2). Serotonin release is inhibited by the E_2 series prostaglandins generated from arachidonic acid, an omega-6 fatty acid that is produced from linoleic acid in animals (152, 153). EPA inhibits the formation of the E_2 series prostaglandins, inhibiting the formation of arachidonic acid in both young and old individuals (154, 155). In rats fed a diet high in arachidonic acid, E_2 series prostaglandins were elevated in the hippocampus, which was attenuated by feeding the rats EPA (156). Because the E_2 series prostaglandins inhibit serotonin release and EPA inhibits the generation of these prostaglandins, it seems likely that EPA in the brain would be important for normal serotonin release. Indeed, human plasma omega-3 levels have been positively correlated with the serotonin metabolite 5-HIAA in cerebral spinal fluid (157). Dietary surveys in the United States indicate that the average adult intakes of linoleic acid (omega-6 fatty acid), α -linolenic acid (omega-3 fatty acid), EPA, and DHA are \sim 12–20, 1.4–2.0, 0.03–0.06, and 0.05–0.10 g/d, respectively (158).

These data suggest that most adults are not getting enough EPA and DHA from their diet.

EPA inhibits inflammation and depression

The E_2 series prostaglandins are hormone-like signaling molecules that play an important role in promoting inflammation, particularly by inducing the production of proinflammatory cytokines such as interleukins IL-6 and IL-1 β and TNF (159). Inflammatory cytokines generated in the periphery are able to cross the blood-brain barrier and cause neuroinflammation. It has been shown that injecting endotoxin in people, which causes an immune response and the production of proinflammatory cytokines, results in depression and inhibition of verbal and nonverbal memory (160). Similarly, intravenous injection of the IFN- γ inflammatory cytokine causes depressive symptoms in people; however, the depression is ameliorated with supplementation with a high dose of EPA (161). Furthermore, individuals with gene polymorphisms in serotonin-related genes have been shown to have an even higher risk of inflammation-induced depression resulting from intravenous injection of IFN- γ (162). Although the link between depression and inflammation has been made, no mechanism has been identified. We think it is likely that the depression that occurs as a consequence of inflammation results from the inhibition of serotonin release, because serotonin also plays an important role in mood. Because serotonin regulates a wide range of cognitive functions and social behaviors in addition to mood, inhibiting the inflammatory E_2 series prostaglandins with EPA has very important serotonin-related therapeutic implications.

DHA regulates serotonin receptor function

We propose another mechanism, that the omega-3 fatty acids modulate the serotonin system is through DHA-mediated regulation of serotonin receptor function, which depends on cell membrane fluidity. DHA is the most abundant fatty acid in the brain, making up 30% of the fatty acid content (163–167). Cell membrane fluidity depends on the amount of cholesterol, which decreases membrane fluidity, and the omega-3 fatty acids in the membrane phospholipids, which increases membrane fluidity. DHA composition in the lipid membrane is necessary for adequate membrane fluidity (167–170). Cholesterol is tightly regulated in the brain, whereas fatty acid composition is influenced by dietary factors. The serotonin receptor is a G protein-coupled receptor that transverses the cell membrane 7 times and is highly influenced by the lipid membrane composition (170–172). As the membrane becomes less fluid, the binding of serotonin to its receptor decreases significantly because serotonin receptors have lower accessibility (173, 174). This effect is not limited to the serotonin receptors but also affects the dopamine receptors and other neurotransmitter receptors (175). DHA's role in membrane fluidity has also been shown to be important for synaptosomal membranes, which regulate neurotransmission (176, 177). Low omega-3 fatty acids have been associated with decreased serotonergic neurotransmission,




Figure 2. Micronutrient regulation of the serotonin pathway. *A*) Tryptophan is transported across the blood-brain barrier, and vitamin D sufficiency allows normal tryptophan metabolism by increasing expression of tryptophan hydroxylase 2 (TPH2) to produce serotonin (5HT). Sufficient levels of eicosapentaenoic acid (EPA) allow 5HT to be released by the presynaptic neuron. Sufficient levels of docosahexaenoic acid (DHA) allow for the binding of 5HT to the serotonin receptor (5HTR) in the postsynaptic neuron. This allows for normal serotonin neurotransmission and executive function, sensory gating, and prosocial behavior. *B*) When vitamin D status is insufficient, TPH2 is not expressed well and little serotonin is produced. Insufficient EPA status results in inhibition of 5HT release from the presynaptic neuron. Insufficient DHA status changes the serotonin receptor accessibility resulting in less 5HT binding to the serotonin receptor on the postsynaptic neuron. This leads to abnormal serotonin neurotransmission and poor executive function, poor sensory gating, and impulsive behavior.

and DHA deficiency decreases the concentration of serotonin in the frontal cortex (178, 179). Because DHA is important for cell membrane fluidity and the serotonin receptor function depends on cell membrane fluidity, this suggests that DHA may be important for serotonin receptor function.

Omega-3 fatty acids regulate neurodevelopment through serotonin

Omega-3 fatty acids play a very important role during brain development, partly through their regulation of the serotonin system. Reduced intake of EPA and DHA during neurodevelopment results in decreased serotonin synthesis, storage, release, and receptor function (164). Omega-3 fatty acid deficiency also affects the structure and wiring of the developing brain as it is associated with a decrease in neurogenesis, dendritic arborization, synaptogenesis, selective pruning, and myelination (164, 165). Perinatal omega-3 deficiency in rats resulted in a 65% reduction in

serotonin levels in the prefrontal cortex and correlated with a 29% reduction in mRNA expression of *tph2* (180). In contrast, supplemental fish oil during gestation and early development increased serotonin levels in the prefrontal cortex of rats and ameliorated stress-induced reductions in serotonin levels (181, 182). Supplementation with omega-3 fatty acids may be very important during pregnancy because the fetus must derive all of its omega-3 fatty acids from the mother by placental transfer (183). Therefore, there is a substantial demand on pregnant and nursing women to provide DHA to their fetuses. The third trimester of gestation is when most of the DHA in the human brain accumulates because this is the time when the brain experiences a growth spurt (184). However, pregnant women consume even less omega-3 fatty acids than the general population, which is already deficient in omega-3, because of the concern over mercury in seafood, the best food source of omega-3 (184). These data suggest that dietary intake of the marine omega-3 fatty acids during pregnancy and early development can modulate the serotonin system.

PROTECTIVE ROLE OF ESTROGEN IN NEUROPSYCHIATRIC ILLNESS

ASD, ADHD, schizophrenia, and impulsive behavior disorders are more prevalent in males than females, whereas bipolar disorder is equally common (22, 185–188). We proposed that this sex difference in ASD is because of the fact that estrogen, a steroid hormone, can replace vitamin D hormone in activating the *TPH2* gene, thus raising serotonin levels (22). Because estrogen significantly increases the expression level of *TPH2* in the brain, serotonin levels would also be raised (189–193). Therefore, we posit that estrogen would also be protective against other neuropsychiatric illnesses. Consistent with this proposal, rats, mice, and humans all have higher tryptophan hydroxylase activity in females compared with males (194–199).

Estrogen increases serotonin synthesis, thus resulting in a protective effect on learning, memory, impulse control, and sensory gating impairments that are experimentally induced during acute tryptophan depletion (200–204). For example, the negative effects of tryptophan depletion on verbal memory are ameliorated in women who are treated with estrogen (201). Estrogen is likely to have positive effects on social behavior, as shown by the fact that women are less aggressive and commit fewer violent crimes and are less likely to commit suicide (78). Acute tryptophan depletion in women in the luteal phase of their menstrual cycle, when estrogen levels are low, causes them to be more aggressive than at other periods of the menstrual cycle when estrogen is more abundant (205). Along the same lines, in postmenopausal women, when estrogen is low, acute tryptophan depletion has significant effects on cognitive function and emotional regulation, reducing working memory and causing hyperactivation of the amygdala, which can be reversed by estrogen administration (200). These data are consistent with the hypothesis that estrogen activation of *TPH2*, and consequently increase in brain serotonin, is a mechanism by which females are somewhat protected from many of the impairments associated with neuropsychiatric disorders including executive function, sensory gating, and social behavior dysfunction.

Although estrogen may play a general protective role against many neuropsychiatric diseases in women, decreases in estrogen levels that occur during the postpartum and postmenopausal periods may leave women vulnerable to mental illness, particularly bipolar disorder, at the time of these biochemical changes. There is a precipitous drop, between 100- and 1000-fold, in estrogen levels during the first 4 months postpartum, possibly exacerbating the effects of already low vitamin D, tryptophan, and omega-3 fatty acid levels (206–208). The postpartum period has been shown to trigger the first presentation of bipolar illness or postpartum psychosis, and during this time, there is a risk for infanticide and maternal suicide, along with other problems in cognitive dysfunction (209, 210). Misdiagnosis of bipolar disorder as postpartum depression is common (211). These data suggest that the postpartum period may present a unique situation where estrogen, vitamin D, tryptophan, and omega-3 levels are all especially low, and this may create an environment for the manifestation of bipolar disorder.

DISCUSSION

We propose that serotonergic dysfunction is a common denominator in a wide range of neuropsychiatric illnesses including ASD, ADHD, bipolar disorder, schizophrenia, impulsive behavior disorders, and depression. This proposal is based on evidence that executive function, sensory gating, and prosocial behavior are all regulated by serotonin and that serotonin levels are low and polymorphisms in serotonin-related genes are common in many of these disorders. We propose that an underlying mechanism is by vitamin D hormone regulating serotonin synthesis, thus modulating the severity of the aforementioned defects. We also provide evidence supporting mechanisms by which EPA regulates the release of serotonin by inhibiting the production of E₂ series prostaglandins and DHA controls serotonin function by increasing neuronal cell membrane fluidity. Our proposed mechanism explains how vitamin D and the marine omega-3 fatty acids work in concert with each other to improve cognitive function, health, and behavior. This synergy can be explained in part by their effects on the serotonin system: vitamin D regulates serotonin synthesis, EPA influences serotonin release, and DHA improves membrane embedded serotonin receptor accessibility. It also partially explains why supplementation with vitamin D, EPA, and DHA improves some behaviors associated with ADHD, bipolar disorder, schizophrenia, and impulsive behavior by controlling serotonin production and function. Although many intervention studies with vitamin D, EPA, and DHA have shown an apparent benefit, larger clinical trials need to be done to determine efficacious doses for these various disorders.

We also review evidence demonstrating how estrogen can overcome the defects on sensory gating and executive function when serotonin is experimentally lowered. We propose that this effect may be caused by estrogen's ability to activate *TPH2*, thus explaining the lower female prevalence in psychiatric disorders. The role of the activating VDRE found in *TPH2* offers a novel explanation of why vitamin D hormone is required for normal serotonin synthesis in the brain and of how low vitamin D could affect the trajectory and development of neuropsychiatric illness. Likewise, estrogen's capacity to boost *TPH2* expression serves as an explanation of why females are more protected from mental illness.

Importantly, because vitamin D regulates the synthesis of serotonin, EPA regulates its release from neurons, and DHA regulates serotonin receptor function, adequate vitamin D and ω -3 fatty acid status would be critical to prevent defects in executive function, impulse control, sensory gating, and prosocial behavior, particularly in the context of a person with a polymorphism in a serotonin-related gene (Fig. 2A). Therefore, inadequate vitamin D and omega-3 fatty acid status, in combination with genetic factors that cause dysfunction in the serotonin pathway, may exacerbate defects and trigger mental illness (Fig. 2B). The timing of vitamin D and/or omega-3 deficiency in combination with genetic propensity for serotonin dysfunction is also likely to be an important determinant of whether mental illness will emerge. In fact, alterations in the migration of GABAergic interneurons during brain development, which is regulated by serotonin, is a key determinant for susceptibility to psychiatric disorders such as schizophrenia and

autism (111). This may partly explain why neonatal vitamin D status is linked to the risk of schizophrenia (98, 120).

Other environmental factors, including stress hormones and inflammatory cytokines, also regulate tryptophan metabolism. Stress hormones and inflammatory cytokines activate the rate-limiting enzymes, indoleamine 2,3-dioxygenase (*IDO*) and tryptophan 2,3-dioxygenase, causing tryptophan to be metabolized to kynurenine instead of serotonin (212). This means that stress and inflammation act as a tryptophan trap, shunting it away from being transported into the brain for serotonin synthesis by *TPH2* (Fig. 1). In the context of prenatal stress, this would mean less maternal serotonin available to shape the developing brain, which has been shown to cause abnormal brain development in mice (110). Furthermore, prenatal stress has also been shown to cause aberrant GABAergic interneuron migration and disrupt serotonin neurons in the developing brain, both of which are associated with increased schizophrenia risk (213, 214). Early stressful events also depress the expression of *TPH2*, which decreases serotonin production in the brain and causes anxious behavior in mice (215). The effects of stress on tryptophan metabolism also lead to a positive feedback loop that ultimately causes a reduction in brain serotonin production and release. This is because of the fact that stress hormones decrease serotonin levels and low serotonin leads to anxious behavior, which results in the production of more stress hormones, thus perpetuating a vicious cycle. In the context of individuals that have polymorphisms in serotonin-related genes, stressful events and micronutrient deficiencies may be the perfect storm to precipitate mental illness. For this reason, it is imperative to break this vicious cycle to normalize serotonin levels and function in the brain while improving behavior.

The nutritional regulators of the serotonin pathway, including vitamin D, EPA, and DHA, are one easy way to intervene and optimize serotonin synthesis and function in the brain. Tryptophan and 5-hydroxytryptophan may be other methods of increasing brain serotonin and have been shown to positively affect mood and lower anxiety (37–39, 216). However, one potential concern with supplementing with tryptophan and 5-hydroxytryptophan is that they may be immediately converted into serotonin in the gastrointestinal tract, which lowers the bioavailability for transport into the brain and is known to cause inflammation (216, 217). Exercise, which increases tryptophan transport into the brain and thus serotonin production, is another simple solution to break the vicious cycle (Fig. 1).

Exercise increases tryptophan transport across the blood-brain barrier by alleviating competition with branch-chain amino acids because muscle preferentially absorbs them (218).

Many individuals with mental illness are deficient in many micronutrients, particularly vitamin D, and ω -3 fatty acids (219). This may explain why supplementation with these essential micronutrients has been shown to be effective for treating symptoms associated with ADHD, bipolar disorder, schizophrenia, impulsive behavior, depression, and obsessive compulsive disorder (142, 220). Furthermore, vitamin D and ω -3 fatty acid supplementation would be a safer therapeutic treatment than serotonin-enhancing drugs, which often have negative side effects (221). Reasonable daily therapeutic doses of ω -3 fatty acids

from fish oil appear to be ≥ 2 g of EPA and 1 g of DHA per day (132). We predict that supplementing with vitamin D, omega-3 fatty acids, and other key micronutrients to reach sufficiently high serum levels will boost serotonin production and function in the brain, thereby improving cognitive function and limiting impulsive behavior. However, the guidelines for vitamin D sufficiency are based on its classical role in bone homeostasis, and it is unclear whether these guidelines are sufficient to maintain non-classical functions of vitamin D hormone in other tissues, including *TPH2* activation in the brain. Other micronutrients that affect the serotonin pathway also appear relevant, such as vitamin B₆ and iron, 2 cofactors involved in serotonin synthesis (Fig. 1). Approximately 8% of the U.S. population is deficient in vitamin B₆; some preliminary evidence suggests that vitamin B₆ may also promote moderate improvements in some behaviors (90, 222, 223). Low iron is also common in 16% of menstruating women and 29% of low-income women; iron supplementation has also been shown to help improve some behaviors (224).

Vitamin D and omega-3 supplementations are practical interventions and are of great therapeutic relevance because of the massive and widespread vitamin D and omega-3 deficiencies in the United States and in particular populations (90, 225). It is likely that relatively small dietary inadequacies in several micronutrients can precipitate a cumulative detrimental effect on the nervous system, thereby compromising cognitive function and behavior. Our findings may have important therapeutic implications for individuals with impulsive aggression toward themselves, as the case with suicide, and aggression toward others. Prisons in the United States are filled with violent offenders who have an abnormally high prevalence of impulsive aggressive behaviors (226). Lowering serotonin synthesis in a person has also been shown to play a causal role in recidivism, suggesting that improving bad behaviors may depend on serotonin levels to some degree (5). This is highly relevant for violent offenders that need to be rehabilitated and suggests that optimizing their micronutrient intake by supplementation with vitamin D, EPA, and DHA may help increase serotonin production and function and thus reduce recidivism. In general, individuals that are prone to short-term decision-making and impulsive behaviors may benefit from supplementation with vitamin D and omega-3 fatty acids. Because vitamin D and omega-3 fatty acid deficiencies are widespread, it is possible that a significant part of the population has sub-clinical deficiencies in serotonin production and function.

Therefore, raising the vitamin D and omega-3 fatty acid levels in the general population by supplementation could result in a concomitant rise in brain serotonin levels and function, therefore increasing normal cognitive function, the propensity for prosocial behavior, and limiting impulsive behaviors. FJ

R.P.P. is grateful for support from the David and Annette Jorgensen Foundation and to the Children's Hospital Oakland Research Institute-Ames Supporting Foundation for the earlier part of this project. The authors thank Henry Wheeler Jr. for generous support of our laboratory. The authors thank Giovanna Ferro-Luzzi Ames, Sam Barondes, Georganne Garfinkel, Mark Haussler, Ron Krauss, Joyce McCann, Daniel Patrick, Margie Profet, and Robert Ryan for comments and suggestions on the manuscript.

Note added in proof: Additionally, mice that were given calcitriol, the hormonally active metabolite of vitamin D, increased the expression of Tph2 and the serotonin metabolite (5-HIAA) in the prefrontal cortex and the hippocampus demonstrating that vitamin D hormone indeed activates Tph2 in the brain (227). It is noteworthy that these mice did not have higher serotonin levels but did have more 5HIAA, suggesting that when serotonin levels are normal, additional vitamin D increases serotonin degradation and does not raise it beyond a physiological normal concentration (227).

REFERENCES

1. Lesch, K. P., Araragi, N., Waider, J., van den Hove, D., and Gutknecht, L. (2012) Targeting brain serotonin synthesis: insights into neurodevelopmental disorders with long-term outcomes related to negative emotionality, aggression and antisocial behaviour. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **367**, 2426–2443
2. Way, B. M., Laćan, G., Fairbanks, L. A., and Melega, W. P. (2007) Architectonic distribution of the serotonin transporter within the orbitofrontal cortex of the vervet monkey. *Neuroscience* **148**, 937–948
3. Varnäs, K., Halldin, C., and Hall, H. (2004) Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. *Hum. Brain Mapp.* **22**, 246–260
4. Sanfey, A. G. (2007) Social decision-making: insights from game theory and neuroscience. *Science* **318**, 598–602
5. Crockett, M. J. (2009) The neurochemistry of fairness: clarifying the link between serotonin and prosocial behavior. *Ann. N. Y. Acad. Sci.* **1167**, 76–86
6. Young, S. N., and Leyton, M. (2002) The role of serotonin in human mood and social interaction. Insight from altered tryptophan levels. *Pharmacol. Biochem. Behav.* **71**, 857–865
7. Blair, R. J. (1995) A cognitive developmental approach to mortality: investigating the psychopath. *Cognition* **57**, 1–29
8. Greenberg, B. D., Li, Q., Lucas, F. R., Hu, S., Sirota, L. A., Benjamin, J., Lesch, K. P., Hamer, D., and Murphy, D. L. (2000) Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. *Am. J. Med. Genet.* **96**, 202–216
9. Retz, W., Retz-Junginger, P., Supprian, T., Thome, J., and Rösler, M. (2004) Association of serotonin transporter promoter gene polymorphism with violence: relation with personality disorders, impulsivity, and childhood ADHD psychopathology. *Behav. Sci. Law* **22**, 415–425
10. Nielsen, D. A., Goldman, D., Virkkunen, M., Tokola, R., Rawlings, R., and Linnoila, M. (1994) Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. *Arch. Gen. Psychiatry* **51**, 34–38
11. Lesch, K. P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., and Murphy, D. L. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. *Science* **274**, 1527–1531
12. Crockett, M. J., Clark, L., Apergis-Schoute, A. M., Morein-Zamir, S., and Robbins, T. W. (2012) Serotonin modulates the effects of Pavlovian aversive predictions on response vigor. *Neuropsychopharmacology* **37**, 2244–2252
13. Crockett, M. J., Clark, L., Lieberman, M. D., Tabibnia, G., and Robbins, T. W. (2010) Impulsive choice and altruistic punishment are correlated and increase in tandem with serotonin depletion. *Emotion* **10**, 855–862
14. Crockett, M. J., Clark, L., and Robbins, T. W. (2009) Reconciling the role of serotonin in behavioral inhibition and aversion: acute tryptophan depletion abolishes punishment-induced inhibition in humans. *J. Neurosci.* **29**, 11993–11999
15. Schmidt, C. W. (2007) Environmental connections: a deeper look into mental illness. *Environ. Health Perspect.* **115**(8), A404–A404, A406–A410
16. Lee, S. H., Ripke, S., Neale, B. M., Faraone, S. V., Purcell, S. M., Perlis, R. H., Mowry, B. J., Thapar, A., Goddard, M. E., Witte, J. S., Absher, D., Agartz, I., Akil, H., Amin, F., Andreassen, O. A., Anjorin, A., Anney, R., Anttila, V., Arking, D. E., Asherson, P., Azevedo, M. H., Backlund, L., Badner, J. A., Bailey, A. J., Banaschewski, T., Barchas, J. D., Barnes, M. R., Barrett, T. B., Bass, N., Battaglia, A., Bauer, M., Bayés, M., Bellivier, F., Bergen, S. E., Berrettini, W., Betancur, C., Bettecken, T., Biederman, J., Binder, E. B., Black, D. W., Blackwood, D. H., Bloss, C. S., Boehnke, M., Boomsma, D. I., Breen, G., Breuer, R., Bruggeman, R., Cormican, P., Buccola, N. G., Buitelaar, J. K., Bunney, W. E., Buxbaum, J. D., Byerley, W. F., Byrne, E. M., Caesar, S., Cahn, W., Cantor, R. M., Casas, M., Chakravarti, A., Chambert, K., Choudhury, K., Cichon, S., Cloninger, C. R., Collier, D. A., Cook, E. H., Coon, H., Cormand, B., Corvin, A., Coryell, W. H., Craig, D. W., Craig, I. W., Crosbie, J., Cuccaro, M. L., Curtis, D., Czamara, D., Datta, S., Dawson, G., Day, R., De Geus, E. J., Degenhardt, F., Djurovic, S., Donohoe, G. J., Doyle, A. E., Duan, J., Dudbridge, F., Duketis, E., Ebstein, R. P., Edenberg, H. J., Elia, J., Ennis, S., Etain, B., Fanous, A., Farmer, A. E., Ferrier, I. N., Flickinger, M., Fombonne, E., Foroud, T., Frank, J., Franke, B., Fraser, C., Freedman, R., Freimer, N. B., Freitag, C. M., Friedl, M., Frisén, L., Gallagher, L., Gejman, P. V., Georgieva, L., Gershon, E. S., Geschwind, D. H., Giegling, I., Gill, M., Gordon, S. D., Gordon-Smith, K., Green, E. K., Greenwood, T. A., Grice, D. E., Gross, M., Grozeva, D., Guan, W., Gurling, H., De Haan, L., Haines, J. L., Hakonarson, H., Hallmayer, J., Hamilton, S. P., Hamshere, M. L., Hansen, T. F., Hartmann, A. M., Hautzinger, M., Heath, A. C., Henders, A. K., Herms, S., Hickie, I. B., Hipolito, M., Hoefels, S., Holmans, P. A., Holsboer, F., Hoogendijk, W. J., Hottenga, J. J., Hultman, C. M., Hus, V., Ingason, A., Ising, M., Jamain, S., Jones, E. G., Jones, I., Jones, L., Tzeng, J. Y., Kähler, A. K., Kahn, R. S., Kandaswamy, R., Keller, M. C., Kennedy, J. L., Kenny, E., Kent, L., Kim, Y., Kirov, G. K., Klauk, S. M., Klei, L., Knowles, J. A., Kohli, M. A., Koller, D. L., Konte, B., Korszun, A., Krabbendam, L., Krasucki, R., Kuntsi, J., Kwan, P., Landén, M., Långström, N., Lathrop, M., Lawrence, J., Lawson, W. B., Leboyer, M., Ledbetter, D. H., Lee, P. H., Lencz, T., Lesch, K. P., Levinson, D. F., Lewis, C. M., Li, J., Lichtenstein, P., Lieberman, J. A., Lin, D. Y., Linszen, D. H., Liu, C., Lohoff, F. W., Loo, S. K., Lord, C., Lowe, J. K., Lucae, S., MacIntyre, D. J., Madden, P. A., Maestrini, E., Magnusson, P. K., Mahon, P. B., Maier, W., Malhotra, A. K., Mane, S. M., Martin, C. L., Martin, N. G., Mattheisen, M., Matthews, K., Mattingdal, M., McCarroll, S. A., McGhee, K. A., McGough, J. J., McGrath, P. J., McGuffin, P., McInnis, M. G., McIntosh, A., McKinney, R., McLean, A. W., McMahon, F. J., McMahon, W. M., McQuillin, A., Medeiros, H., Medland, S. E., Meier, S., Melle, I., Meng, F., Meyer, J., Middeldorp, C. M., Middleton, L., Milanova, V., Miranda, A., Monaco, A. P., Montgomery, G. W., Moran, J. L., Moreno-De-Luca, D., Morken, G., Morris, D. W., Morrow, E. M., Moskva, V., Muglia, P., Mühleisen, T. W., Muir, W. J., Müller-Myhsok, B., Murtha, M., Myers, R. M., Myin-Germeys, I., Neale, M. C., Nelson, S. F., Nievergelt, C. M., Nikolov, I., Nimgaonkar, V., Nolen, W. A., Nöthen, M. M., Nurnberger, J. I., Nwulia, E. A., Nyholt, D. R., O'Dushlaine, C., Oades, R. D., Olincy, A., Oliveira, G., Olsen, L., Ophoff, R. A., Osby, U., Owen, M. J., Palotie, A., Parr, J. R., Paterson, A. D., Pato, C. N., Pato, M. T., Penninx, B. W., Pergadia, M. L., Pericak-Vance, M. A., Pickard, B. S., Pimm, J., Piven, J., Posthuma, D., Potash, J. B., Poustka, F., Propping, P., Puri, V., Quedsted, D. J., Quinn, E. M., Ramos-Quiroga, J. A., Rasmussen, H. B., Raychaudhuri, S., Rehnström, K., Reif, A., Ribasés, M., Rice, J. P., Rietschel, M., Roeder, K., Roeyers, H., Rossin, L., Rothenberger, A., Rouleau, G., Ruderfer, D., Rujescu, D., Sanders, A. R., Sanders, S. J., Santangelo, S. L., Sergeant, J. A., Schachar, R., Schalling, M., Schatzberg, A. F., Scheftner, W. A., Schellenberg, G. D., Scherer, S. W., Schork, N. J., Schulze, T. G., Schumacher, J., Schwarz, M., Scolnick, E., Scott, L. J., Shi, J., Shilling, P. D., Shyn, S. I., Silverman, J. M., Slager, S. L., Smalley, S. L., Smit, J. H., Smith, E. N., Sonuga-Barke, E. J., St Clair, D., State, M., Steffens, M., Steinhausen, H. C., Strauss, J. S., Strohmaier, J., Stroup, T. S., Sutcliffe, J. S., Szatmari, P., Szlinger, S., Thirumalai, S., Thompson, R. C., Todorov, A. A., Tozzi, F., Treutlein, J., Uhr, M., van den Oord, E. J., Van Grootheest, G., Van Os, J., Vicente, A. M., Vieland, V. J., Vincent, J. B., Visscher, P. M., Walsh, C. A., Wassink, T. H., Watson, S. J., Weissman, M. M., Werge, T., Wienker, T. F., Wijsman, E. M., Willemsen, G.,

- Williams, N., Willsey, A. J., Witt, S. H., Xu, W., Young, A. H., Yu, T. W., Zammit, S., Zandi, P. P., Zhang, P., Zitman, F. G., Zöllner, S., Devlin, B., Kelseo, J. R., Sklar, P., Daly, M. J., O'Donovan, M. C., Craddock, N., Sullivan, P. F., Smoller, J. W., Kendler, K. S., and Wray, N. R.; Cross-Disorder Group of the Psychiatric Genomics Consortium; International Inflammatory Bowel Disease Genetics Consortium (IIBDGC). (2013) Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat. Genet.* **45**, 984–994
17. Meaney, M. J. (2010) Epigenetics and the biological definition of gene x environment interactions. *Child Dev.* **81**, 41–79
 18. Bevilacqua, L., Doly, S., Kaprio, J., Yuan, Q., Tikkanen, R., Paunio, T., Zhou, Z., Wedenoja, J., Maroteaux, L., Diaz, S., Belmer, A., Hodgkinson, C. A., Dell'osso, L., Suvisaari, J., Coccaro, E., Rose, R. J., Peltonen, L., Virkkunen, M., and Goldman, D. (2010) A population-specific HTR2B stop codon predisposes to severe impulsivity. *Nature* **468**, 1061–1066
 19. Rogers, R. D., Tunbridge, E. M., Bhagwagar, Z., Drevets, W. C., Sahakian, B. J., and Carter, C. S. (2003) Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. *Neuropsychopharmacology* **28**, 153–162
 20. Crockett, M. J., Clark, L., Hauser, M. D., and Robbins, T. W. (2010) Serotonin selectively influences moral judgment and behavior through effects on harm aversion. *Proc. Natl. Acad. Sci. USA* **107**, 17433–17438
 21. Parletta, N., Milte, C. M., and Meyer, B. J. (2013) Nutritional modulation of cognitive function and mental health. *J. Nutr. Biochem.* **24**, 725–743
 22. Patrick, R. P., and Ames, B. N. (2014) Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. *FASEB J.* **28**, 2398–2413
 23. Reilly, J. G., McTavish, S. F., and Young, A. H. (1997) Rapid depletion of plasma tryptophan: a review of studies and experimental methodology. *J. Psychopharmacol. (Oxford)* **11**, 381–392
 24. Rogers, R. D., Everitt, B. J., Baldacchino, A., Blackshaw, A. J., Swanson, R., Wynne, K., Baker, N. B., Hunter, J., Carthy, T., Booker, E., London, M., Deakin, J. F., Sahakian, B. J., and Robbins, T. W. (1999) Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. *Neuropsychopharmacology* **20**, 322–339
 25. Robbins, T. W., and Crockett, M. J. (2010) Role of central serotonin in impulsivity and compulsivity: comparative studies in experimental animals and humans. *Handbook Behav. Neurosci.* **21**, 415–427
 26. Crockett, M. J., Clark, L., Tabibnia, G., Lieberman, M. D., and Robbins, T. W. (2008) Serotonin modulates behavioral reactions to unfairness. *Science* **320**, 1739
 27. Schweighofer, N., Bertin, M., Shishida, K., Okamoto, Y., Tanaka, S. C., Yamawaki, S., and Doya, K. (2008) Low-serotonin levels increase delayed reward discounting in humans. *J. Neurosci.* **28**, 4528–4532
 28. Tanaka, S. C., Schweighofer, N., Asahi, S., Shishida, K., Okamoto, Y., Yamawaki, S., and Doya, K. (2007) Serotonin differentially regulates short- and long-term prediction of rewards in the ventral and dorsal striatum. *PLoS ONE* **2**, e1333
 29. Mann, C., Croft, R. J., Scholes, K. E., Dunne, A., O'Neill, B. V., Leung, S., Copolov, D., Phan, K. L., and Nathan, P. J. (2008) Differential effects of acute serotonin and dopamine depletion on prepulse inhibition and p50 suppression measures of sensorimotor and sensory gating in humans. *Neuropsychopharmacology* **33**, 1653–1666
 30. Phillips, M. A., Oxtoby, E. K., Langley, R. W., Bradshaw, C. M., and Szabadi, E. (2000) Effects of acute tryptophan depletion on prepulse inhibition of the acoustic startle (eyeblink) response and the N1/P2 auditory evoked response in man. *J. Psychopharmacol. (Oxford)* **14**, 258–265
 31. Seo, D., Patrick, C. J., and Kennealy, P. J. (2008) Role of Serotonin and Dopamine System Interactions in the Neurobiology of Impulsive Aggression and its Comorbidity with other Clinical Disorders. *Aggress. Violent. Behav.* **13**, 383–395
 32. Wood, R. M., Rilling, J. K., Sanfey, A. G., Bhagwagar, Z., and Rogers, R. D. (2006) Effects of tryptophan depletion on the performance of an iterated Prisoner's Dilemma game in healthy adults. *Neuropsychopharmacology* **31**, 1075–1084
 33. Cleare, A. J., and Bond, A. J. (1995) The effect of tryptophan depletion and enhancement on subjective and behavioural aggression in normal male subjects. *Psychopharmacology (Berl.)* **118**, 72–81
 34. Passamonti, L., Crockett, M. J., Apergis-Schoute, A. M., Clark, L., Rowe, J. B., Calder, A. J., and Robbins, T. W. (2012) Effects of acute tryptophan depletion on prefrontal-amygdala connectivity while viewing facial signals of aggression. *Biol. Psychiatry* **71**, 36–43
 35. Fikke, L. T., Melinder, A., and Landrø, N. I. (2013) The effects of acute tryptophan depletion on impulsivity and mood in adolescents engaging in non-suicidal self-injury. *Hum. Psychopharmacol.* **28**, 61–71
 36. Zepf, F. D., Stadler, C., Demisch, L., Schmitt, M., Landgraf, M., and Poustka, F. (2008) Serotonergic functioning and trait-impulsivity in attention-deficit/hyperactivity-disordered boys (ADHD): influence of rapid tryptophan depletion. *Hum. Psychopharmacol.* **23**, 43–51
 37. Hudson, C., Hudson, S., and MacKenzie, J. (2007) Protein-source tryptophan as an efficacious treatment for social anxiety disorder: a pilot study. *Can. J. Physiol. Pharmacol.* **85**, 928–932
 38. Young, S. N., Rot, M., Pinard, G., and Moskowitz, D. S. (2007) The effect of tryptophan on quarrelsomeness, agreeableness, and mood in everyday life. *Int. Congr. Ser.* **1304**, 133–143
 39. van der Rot, M., Moskowitz, D. S., Pinard, G., and Young, S. N. (2006) Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals. *J. Psychiatry Neurosci.* **31**, 253–262
 40. Moskowitz, D. S., Pinard, G., Zuroff, D. C., Annable, L., and Young, S. N. (2001) The effect of tryptophan on social interaction in everyday life: a placebo-controlled study. *Neuropsychopharmacology* **25**, 277–289
 41. Nantel-Vivier, A., Pihl, R. O., Young, S. N., Parent, S., Bélanger, S. A., Sutton, R., Dubois, M. E., Tremblay, R. E., and Séguin, J. R. (2011) Serotonergic contribution to boys' behavioral regulation. *PLoS ONE* **6**, e20304
 42. Volavka, J., Crowner, M., Brizer, D., Convit, A., Van Praag, H., and Suckow, R. F. (1990) Tryptophan treatment of aggressive psychiatric inpatients. *Biol. Psychiatry* **28**, 728–732
 43. Morand, C., Young, S. N., and Ervin, F. R. (1983) Clinical response of aggressive schizophrenics to oral tryptophan. *Biol. Psychiatry* **18**, 575–578
 44. Mehlman, P. T., Higley, J. D., Faucher, I., Lilly, A. A., Taub, D. M., Vickers, J., Suomi, S. J., and Linnoila, M. (1994) Low CSF 5-HIAA concentrations and severe aggression and impaired impulse control in nonhuman primates. *Am. J. Psychiatry* **151**, 1485–1491
 45. Gibbons, J. L., Barr, G. A., Bridger, W. H., and Leibowitz, S. F. (1979) Manipulations of dietary tryptophan: effects on mouse killing and brain serotonin in the rat. *Brain Res.* **169**, 139–153
 46. Molina, V., Ciesielski, L., Gobaïlle, S., Isef, F., and Mandel, P. (1987) Inhibition of mouse killing behavior by serotonin-mimetic drugs: effects of partial alterations of serotonin neurotransmission. *Pharmacol. Biochem. Behav.* **27**, 123–131
 47. Mosienko, V., Bert, B., Beis, D., Matthes, S., Fink, H., Bader, M., and Alenina, N. (2012) Exaggerated aggression and decreased anxiety in mice deficient in brain serotonin. *Transl. Psychiatr.* **2**, e122
 48. Osipova, D. V., Kulikov, A. V., and Popova, N. K. (2009) C1473G polymorphism in mouse tph2 gene is linked to tryptophan hydroxylase-2 activity in the brain, intermale aggression, and depressive-like behavior in the forced swim test. *J. Neurosci. Res.* **87**, 1168–1174
 49. Angoa-Pérez, M., Kane, M. J., Briggs, D. I., Herrera-Mundo, N., Sykes, C. E., Francescutti, D. M., and Kuhn, D. M. (2014) Mice genetically depleted of brain serotonin do not display a depression-like behavioral phenotype. *ACS Chem. Neurosci.* **5**, 908–919
 50. Moreno-De-Luca, A., Myers, S. M., Challman, T. D., Moreno-De-Luca, D., Evans, D. W., and Ledbetter, D. H. (2013) Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence. *Lancet Neurol.* **12**, 406–414
 51. Capute, A. J., and Palmer, F. B. (1980) A pediatric overview of the spectrum of developmental disabilities. *J. Dev. Behav. Pediatr.* **1**, 66–69
 52. Batshaw, M.L., Lotrecchiano, G.R., and Roizen, N.J. (2013) *Diagnosis of Developmental Disabilities* Vol. 7, Paul H. Brookes Publishing Co., Baltimore

53. Perry, W., Minassian, A., Lopez, B., Maron, L., and Lincoln, A. (2007) Sensorimotor gating deficits in adults with autism. *Biol. Psychiatry* **61**, 482–486
54. Javanbakht, A. (2006) Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia. *Med. Hypotheses* **67**, 1173–1184
55. Holstein, D. H., Vollenweider, F. X., Geyer, M. A., Csomor, P. A., Belsler, N., and Eich, D. (2013) Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD). *Psychiatry Res.* **205**, 117–126
56. Lijffijt, M., Moeller, F. G., Boutros, N. N., Burroughs, S., Steinberg, J. L., Lane, S. D., and Swann, A. C. (2009) A pilot study revealing impaired P50 gating in antisocial personality disorder. *J. Neuropsychiatry Clin. Neurosci.* **21**, 328–331
57. Lijffijt, M., Moeller, F. G., Boutros, N. N., Steinberg, J. L., Meier, S. L., Lane, S. D., and Swann, A. C. (2009) Diminished P50, N100 and P200 auditory sensory gating in bipolar I disorder. *Psychiatry Res.* **167**, 191–201
58. Olincy, A., and Martin, L. (2005) Diminished suppression of the P50 auditory evoked potential in bipolar disorder subjects with a history of psychosis. *Am. J. Psychiatry* **162**, 43–49
59. Mahmood, T., and Silverstone, T. (2001) Serotonin and bipolar disorder. *J. Affect. Disord.* **66**, 1–11
60. Flory, J. D., Newcorn, J. H., Miller, C., Hart, S., and Halperin, J. M. (2007) Serotonergic function in children with attention-deficit hyperactivity disorder: relationship to later antisocial personality disorder. *Br. J. Psychiatry* **190**, 410–414
61. Cooper, S. J., Kelly, C. B., and King, D. J. (1992) 5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behaviour in schizophrenia. *Lancet* **340**, 940–941
62. Brown, G. L., and Linnoila, M. I. (1990) CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. *J. Clin. Psychiatry* **51**(Suppl), 31–41
63. Placidi, G. P., Oquendo, M. A., Malone, K. M., Huang, Y. Y., Ellis, S. P., and Mann, J. J. (2001) Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fluid monoamine metabolite levels. *Biol. Psychiatry* **50**, 783–791
64. Stanley, B., Molcho, A., Stanley, M., Winchel, R., Gameroff, M. J., Parsons, B., and Mann, J. J. (2000) Association of aggressive behavior with altered serotonergic function in patients who are not suicidal. *Am. J. Psychiatry* **157**, 609–614
65. Brown, G. L., Goodwin, F. K., Ballenger, J. C., Goyer, P. F., and Major, L. F. (1979) Aggression in humans correlates with cerebrospinal fluid amine metabolites. *Psychiatry Res.* **1**, 131–139
66. Träskman-Bendz, L., Asberg, M., and Schalling, D. (1986) Serotonergic function and suicidal behavior in personality disorders. *Ann. N. Y. Acad. Sci.* **487**, 168–174
67. Lidberg, L., Tuck, J. R., Asberg, M., Scalia-Tomba, G. P., and Bertilsson, L. (1985) Homicide, suicide and CSF 5-HIAA. *Acta Psychiatr. Scand.* **71**, 230–236
68. Virkkunen, M., De Jong, J., Bartko, J., Goodwin, F. K., and Linnoila, M. (1989) Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters. A follow-up study. *Arch. Gen. Psychiatry* **46**, 600–603
69. Faraone, S. V., and Mick, E. (2010) Molecular genetics of attention deficit hyperactivity disorder. *Psychiatr. Clin. North Am.* **33**, 159–180
70. Bellivier, F., Leboyer, M., Courtet, P., Buresi, C., Beaufile, B., Samolyk, D., Allilaire, J. F., Feingold, J., Mallet, J., and Malafosse, A. (1998) Association between the tryptophan hydroxylase gene and manic-depressive illness. *Arch. Gen. Psychiatry* **55**, 33–37
71. Cichon, S., Winge, I., Mattheisen, M., Georgi, A., Karpushova, A., Freudenberger, J., Freudenberger-Hua, Y., Babadjanova, G., Van Den Bogaert, A., Abramova, L. I., Kapiletti, S., Knappskog, P. M., McKinney, J., Maier, W., Jamra, R. A., Schulze, T. G., Schumacher, J., Propping, P., Rietschel, M., Haavik, J., and Nöthen, M. M. (2008) Brain-specific tryptophan hydroxylase 2 (TPH2): a functional Pro206Ser substitution and variation in the 5'-region are associated with bipolar affective disorder. *Hum. Mol. Genet.* **17**, 87–97
72. Chotai, J., Serretti, A., and Lorenzi, C. (2005) Interaction between the tryptophan hydroxylase gene and the serotonin transporter gene in schizophrenia but not in bipolar or unipolar affective disorders. *Neuropsychobiology* **51**, 3–9
73. Rujescu, D., Giegling, I., Bondy, B., Gietl, A., Zill, P., and Möller, H. J. (2002) Association of anger-related traits with SNPs in the TPH gene. *Mol. Psychiatry* **7**, 1023–1029
74. Evans, J., Reeves, B., Platt, H., Leibenau, A., Goldman, D., Jefferson, K., and Nutt, D. (2000) Impulsiveness, serotonin genes and repetition of deliberate self-harm (DSH). *Psychol. Med.* **30**, 1327–1334
75. Van Den Bogaert, A., Slegers, K., De Zutter, S., Heyrman, L., Norrback, K. F., Adolfsson, R., Van Broeckhoven, C., and DelFavero, J. (2006) Association of brain-specific tryptophan hydroxylase, TPH2, with unipolar and bipolar disorder in a Northern Swedish, isolated population. *Arch. Gen. Psychiatry* **63**, 1103–1110
76. Zill, P., Baghai, T. C., Zwanzger, P., Schüle, C., Eser, D., Rupprecht, R., Möller, H. J., Bondy, B., and Ackenheil, M. (2004) SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. *Mol. Psychiatry* **9**, 1030–1036
77. Hovatta, I., and Barlow, C. (2008) Molecular genetics of anxiety in mice and men. *Ann. Med.* **40**, 92–109
78. Craig, I. W., and Halton, K. E. (2009) Genetics of human aggressive behaviour. *Hum. Genet.* **126**, 101–113
79. Zalsman, G., Patya, M., Frisch, A., Ofek, H., Schapir, L., Blum, I., Harell, D., Apter, A., Weizman, A., and Tyano, S. (2011) Association of polymorphisms of the serotonergic pathways with clinical traits of impulsive-aggression and suicidality in adolescents: a multi-center study. *World J. Biol. Psychiatry* **12**, 33–41
80. Abbar, M., Courtet, P., Bellivier, F., Leboyer, M., Boulenger, J. P., Castelhou, D., Ferreira, M., Lambercy, C., Mouthon, D., Paoloni-Giacobino, A., Vessaz, M., Malafosse, A., and Buresi, C. (2001) Suicide attempts and the tryptophan hydroxylase gene. *Mol. Psychiatry* **6**, 268–273
81. Grudet, C., Malm, J., Westrin, A., and Brunelin, L. (2014) Suicidal patients are deficient in vitamin D, associated with a pro-inflammatory status in the blood. *Psychoneuroendocrinology* **50**, 210–219
82. Vyssocki, B., Kapusta, N. D., Prashak-Rieder, N., Dorffner, G., and Willeit, M. (2014) Direct effect of sunshine on suicide. *JAMA Psychiatry* **71**, 1231–1237
83. Vyssocki, B., Prashak-Rieder, N., Sonneck, G., Blüml, V., Willeit, M., Kasper, S., and Kapusta, N. D. (2012) Effects of sunshine on suicide rates. *Compr. Psychiatry* **53**, 535–539
84. Holick, M. F., and Chen, T. C. (2008) Vitamin D deficiency: a worldwide problem with health consequences. *Am. J. Clin. Nutr.* **87**, 1080S–1086S
85. Wang, T. T., Tavera-Mendoza, L. E., Laperriere, D., Libby, E., MacLeod, N. B., Nagai, Y., Bourdeau, V., Konstorum, A., Lallemand, B., Zhang, R., Mader, S., and White, J. H. (2005) Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. *Mol. Endocrinol.* **19**, 2685–2695
86. Haussler, M. R., Jurutka, P. W., Mizwicki, M., and Norman, A. W. (2011) Vitamin D receptor (VDR)-mediated actions of 1 α ,25(OH) $_2$ vitamin D $_3$: genomic and non-genomic mechanisms. *Best Pract. Res. Clin. Endocrinol. Metab.* **25**, 543–559
87. Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A., Heaney, R. P., Murad, M. H., and Weaver, C. M.; Endocrine Society. (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J. Clin. Endocrinol. Metab.* **96**, 1911–1930
88. Kennel, K. A., Drake, M. T., and Hurley, D. L. (2010) Vitamin D deficiency in adults: when to test and how to treat. *Mayo Clinic Proc.* **85**, 752–757
89. Ginde, A. A., Liu, M. C., and Camargo, C. A., Jr. (2009) Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. *Arch. Intern. Med.* **169**, 626–632
90. Bailey, R. L., Fulgoni, V. L., 3rd, Keast, D. R., Dwyer, J. T. (2012) Examination of vitamin intakes among US adults by dietary supplement use. *J. Acad. Nutr. Dietetics* **112**, 657–663
91. Mansbach, J. M., Ginde, A. A., and Camargo, C. A., Jr. (2009) Serum 25-hydroxyvitamin D levels among US children aged 1 to 11 years: do children need more vitamin D? *Pediatrics* **124**, 1404–1410
92. McCann, J. C., and Ames, B. N. (2008) Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? *FASEB J.* **22**, 982–1001

93. Holick, M. F. (2006) High prevalence of vitamin D inadequacy and implications for health. *Mayo Clinic Proc.* **81**, 353–373
94. Byrdwell, W. C., Devries, J., Exler, J., Harnly, J. M., Holden, J. M., Holick, M. F., Hollis, B. W., Horst, R. L., Lada, M., Lemar, L. E., Patterson, K. Y., Phillips, K. M., Tarrago-Trani, M. T., and Wolf, W. R. (2008) Analyzing vitamin D in foods and supplements: methodologic challenges. *Am. J. Clin. Nutr.* **88**, 554S–557S
95. Bloom, G., and Sherman, P. W. (2005) Dairying barriers affect the distribution of lactose malabsorption. *Evol. Hum. Behav.* **26**, 301–312
96. Goksugur, S. B., Tufan, A. E., Semiz, M., Gunes, C., Bekdas, M., Tosun, M., Demircioglu, F. (2014) Vitamin D status in children with attention deficit hyperactivity disorder. *Pediatrics Int.* **56**, 515–519
97. McGrath, J., Eyles, D., Mowry, B., Yolken, R., and Buka, S. (2003) Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. *Schizophr. Res.* **63**, 73–78
98. McGrath, J. J., Eyles, D. W., Pedersen, C. B., Anderson, C., Ko, P., Burne, T. H., Norgaard-Pedersen, B., Hougaard, D. M., and Mortensen, P. B. (2010) Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. *Arch. Gen. Psychiatry* **67**, 889–894
99. Kinney, D. K., Teixeira, P., Hsu, D., Napoleon, S. C., Crowley, D. J., Miller, A., Hyman, W., and Huang, E. (2009) Relation of schizophrenia prevalence to latitude, climate, fish consumption, infant mortality, and skin color: a role for prenatal vitamin D deficiency and infections? *Schizophr. Bull.* **35**, 582–595
100. Tolppanen, A. M., Sayers, A., Fraser, W. D., Lewis, G., Zammit, S., and Lawlor, D. A. (2012) The association of 25-hydroxyvitamin D3 and D2 with behavioural problems in childhood. *PLoS ONE* **7**, e40097
101. Ubbenhorst, A., Striebich, S., Lang, F., and Lang, U. E. (2011) Exploring the relationship between vitamin D and basic personality traits. *Psychopharmacology (Berl.)* **215**, 733–737
102. Chotai, J., Serretti, A., Lattuada, E., Lorenzi, C., and Lilli, R. (2003) Gene-environment interaction in psychiatric disorders as indicated by season of birth variations in tryptophan hydroxylase (TPH), serotonin transporter (5-HTTLPR) and dopamine receptor (DRD4) gene polymorphisms. *Psychiatry Res.* **119**, 99–111
103. Zhang, X., Beaulieu, J. M., Sotnikova, T. D., Gainetdinov, R. R., and Caron, M. G. (2004) Tryptophan hydroxylase-2 controls brain serotonin synthesis. *Science* **305**, 217
104. Groves, N. J., Kesby, J. P., Eyles, D. W., McGrath, J. J., Mackay-Sim, A., and Burne, T. H. (2013) Adult vitamin D deficiency leads to behavioural and brain neurochemical alterations in C57BL/6J and BALB/c mice. *Behav. Brain Res.* **241**, 120–131
105. Turner, K. M., Young, J. W., McGrath, J. J., Eyles, D. W., and Burne, T. H. (2013) Cognitive performance and response inhibition in developmentally vitamin D (DVD)-deficient rats. *Behav. Brain Res.* **242**, 47–53
106. Becker, A., Eyles, D. W., McGrath, J. J., and Grecksch, G. (2005) Transient prenatal vitamin D deficiency is associated with subtle alterations in learning and memory functions in adult rats. *Behav. Brain Res.* **161**, 306–312
107. Burne, T. H., McGrath, J. J., Eyles, D. W., and Mackay-Sim, A. (2005) Behavioural characterization of vitamin D receptor knockout mice. *Behav. Brain Res.* **157**, 299–308
108. Kaluff, A. V., Keisala, T., Minasyan, A., Kuuslahti, M., Miettinen, S., and Tuohimaa, P. (2006) Behavioural anomalies in mice evoked by “Tokyo” disruption of the Vitamin D receptor gene. *Neurosci. Res.* **54**, 254–260
109. Byrne, J. H., Voogt, M., Turner, K. M., Eyles, D. W., McGrath, J. J., and Burne, T. H. (2013) The impact of adult vitamin D deficiency on behaviour and brain function in male Sprague-Dawley rats. *PLoS ONE* **8**, e71593
110. Côté, F., Fligny, C., Bayard, E., Launay, J. M., Gershon, M. D., Mallet, J., and Vojtdani, G. (2007) Maternal serotonin is crucial for murine embryonic development. *Proc. Natl. Acad. Sci. USA* **104**, 329–334
111. Dayer, A. (2014) Serotonin-related pathways and developmental plasticity: relevance for psychiatric disorders. *Dialoques Clin. Neurosci.* **16**, 29–41
112. Eyles, D. W., Feron, F., Cui, X., Kesby, J. P., Harms, L. H., Ko, P., McGrath, J. J., and Burne, T. H. (2009) Developmental vitamin D deficiency causes abnormal brain development. *Psychoneuroendocrinology* **34**(Suppl 1), S247–S257
113. Eyles, D., Brown, J., Mackay-Sim, A., McGrath, J., and Feron, F. (2003) Vitamin D3 and brain development. *Neuroscience* **118**, 641–653
114. Annweiler, C., Montero-Odasso, M., Hachinski, V., Seshadri, S., Bartha, R., and Beauchet, O. (2013) Vitamin D concentration and lateral cerebral ventricle volume in older adults. *Mol. Nutr. Food Res.* **57**, 267–276
115. Gilmore, J. H., Smith, L. C., Wolfe, H. M., Hertzberg, B. S., Smith, J. K., Chescheir, N. C., Evans, D. D., Kang, C., Hamer, R. M., Lin, W., and Gerig, G. (2008) Prenatal mild ventriculomegaly predicts abnormal development of the neonatal brain. *Biol. Psychiatry* **64**, 1069–1076
116. Fearon, P., and Jones, P. B., Kennedy. (2004) Raised incidence of psychosis in all migrant groups in South London, Nottingham and Bristol: the ÆSOP Study. *Schizophr. Res.* **67**
117. Jarvis, E. (1998) Schizophrenia in British immigrants: recent findings, issues and implications. *Transcult. Psychiatry* **35**, 39–74
118. King, M., Nazroo, J., Weich, S., McKenzie, K., Bhui, K., Karlsen, S., Stansfeld, S., Tyrer, P., Blanchard, M., Lloyd, K., McManus, S., Sproston, K., and Erens, B. (2005) Psychotic symptoms in the general population of England—a comparison of ethnic groups (The EMPIRIC study). *Soc. Psychiatry Psychiatr. Epidemiol.* **40**, 375–381
119. Berg, A. O., Melle, I., Torjesen, P. A., Lien, L., Hauff, E., and Andreassen, O. A. (2010) A cross-sectional study of vitamin D deficiency among immigrants and Norwegians with psychosis compared to the general population. *J. Clin. Psychiatry* **71**, 1598–1604
120. McGrath, J., Saari, K., Hakko, H., Jokelainen, J., Jones, P., Järvelin, M. R., Chant, D., and Isohanni, M. (2004) Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. *Schizophr. Res.* **67**, 237–245
121. Tolppanen, A. M., Sayers, A., Fraser, W. D., Lewis, G., Zammit, S., McGrath, J., and Lawlor, D. A. (2012) Serum 25-hydroxyvitamin D3 and D2 and non-clinical psychotic experiences in childhood. *PLoS ONE* **7**, e41575
122. Gracious, B. L., Finucane, T. L., Friedman-Campbell, M., Messing, S., and Parkhurst, M. N. (2012) Vitamin D deficiency and psychotic features in mentally ill adolescents: a cross-sectional study. *BMC Psychiatry* **12**, 38
123. Belvederi Murri, M., Respino, M., Masotti, M., Innamorati, M., Mondelli, V., Pariante, C., and Amore, M. (2013) Vitamin D and psychosis: mini meta-analysis. *Schizophr. Res.* **150**, 235–239
124. Rylander, M., and Verhulst, S. (2013) Vitamin D insufficiency in psychiatric inpatients. *J. Psychiatr. Pract.* **19**, 296–300
125. Anglin, R. E., Samaan, Z., Walter, S. D., and McDonald, S. D. (2013) Vitamin D deficiency and depression in adults: systematic review and meta-analysis. *Br. J. Psychiatry* **202**, 100–107
126. Hossein-nezhad, A., and Holick, M. F. (2012) Optimize dietary intake of vitamin D: an epigenetic perspective. *Curr. Opin. Clin. Nutr. Metab. Care* **15**, 567–579
127. Bodnar, L. M., Simhan, H. N., Powers, R. W., Frank, M. P., Cooperstein, E., and Roberts, J. M. (2007) High prevalence of vitamin D insufficiency in black and white pregnant women residing in the northern United States and their neonates. *J. Nutr.* **137**, 447–452
128. Hollis, B. W., Johnson, D., Hulsey, T. C., Ebeling, M., Wagner, C. L. (2011) Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. *J. Bone Miner. Res.* **26**, 2341–2357
129. Rucklidge, J. J., Frampton, C. M., Gorman, B., and Boggis, A. (2014) Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial. *Br. J. Psychiatry* **204**, 306–315
130. Rucklidge, J. J., Johnstone, J., Gorman, B., Boggis, A., and Frampton, C. M. (2014) Moderators of treatment response in adults with ADHD treated with a vitamin-mineral supplement. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **50**, 163–171
131. Chan, E. J., and Cho, L. (2009) What can we expect from omega-3 fatty acids? *Cleve. Clin. J. Med.* **76**, 245–251
132. Sinn, N., Milte, C., and Howe, P. R. (2010) Oiling the brain: a review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan. *Nutrients* **2**, 128–170

133. Amminger, G. P., and McGorry, P. D. (2012) Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders. *Neuropsychopharmacology* **37**, 309–310
134. Sorgi, P. J., Hallowell, E. M., Hutchins, H. L., and Sears, B. (2007) Effects of an open-label pilot study with high-dose EPA/DHA concentrates on plasma phospholipids and behavior in children with attention deficit hyperactivity disorder. *Nutr. J.* **6**, 16
135. Pomponi, M., Janiri, L., La Torre, G., Di Stasio, E., Di Nicola, M., Mazza, M., Martinotti, G., Bria, P., Lippa, S., Natili, R., and Pomponi, M. F. (2013) Plasma levels of n-3 fatty acids in bipolar patients: deficit restricted to DHA. *J. Psychiatr. Res.* **47**, 337–342
136. Huan, M., Hamazaki, K., Sun, Y., Itomura, M., Liu, H., Kang, W., Watanabe, S., Terasawa, K., and Hamazaki, T. (2004) Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China. *Biol. Psychiatry* **56**, 490–496
137. McNamara, R. K., Jandacek, R., Rider, T., Tso, P., Hahn, C. G., Richtand, N. M., and Stanford, K. E. (2007) Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications. *Schizophr. Res.* **91**, 37–50
138. Lopez, V. A., Detera-Wadleigh, S., Cardona, I., Kassem, L., and McMahon, F. J.; National Institute of Mental Health Genetics Initiative Bipolar Disorder Consortium. (2007) Nested association between genetic variation in tryptophan hydroxylase II, bipolar affective disorder, and suicide attempts. *Biol. Psychiatry* **61**, 181–186
139. Sublette, M. E., Hibbeln, J. R., Galfalvy, H., Oquendo, M. A., and Mann, J. J. (2006) Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. *Am. J. Psychiatry* **163**, 1100–1102
140. Hallahan, B., Hibbeln, J. R., Davis, J. M., and Garland, M. R. (2007) Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. *Br. J. Psychiatry* **190**, 118–122
141. Conklin, S. M., Harris, J. L., Manuck, S. B., Yao, J. K., Hibbeln, J. R., and Muldoon, M. F. (2007) Serum omega-3 fatty acids are associated with variation in mood, personality and behavior in hypercholesterolemic community volunteers. *Psychiatry Res.* **152**, 1–10
142. Hamazaki, T., and Hamazaki, K. (2008) Fish oils and aggression or hostility. *Prog. Lipid Res.* **47**, 221–232
143. Buydens-Branchey, L., Branchey, M., and Hibbeln, J. R. (2008) Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **32**, 568–575
144. Appleton, K. M., Fraser, W. D., Rogers, P. J., Ness, A. R., and Tobias, J. H. (2011) Supplementation with a low-moderate dose of n-3 long-chain PUFA has no short-term effect on bone resorption in human adults. *Br. J. Nutr.* **105**, 1145–1149
145. Appleton, K. M., Rogers, P. J., and Ness, A. R. (2010) Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. *Am. J. Clin. Nutr.* **91**, 757–770
146. Martins, J. G. (2009) EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. *J. Am. Coll. Nutr.* **28**, 525–542
147. Ross, B. M., Seguin, J., and Sieswerda, L. E. (2007) Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? *Lipids Health Dis.* **6**, 21
148. Sublette, M. E., Ellis, S. P., Geant, A. L., and Mann, J. J. (2011) Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. *J. Clin. Psychiatry* **72**, 1577–1584
149. Bloch, M. H., and Hannestad, J. (2012) Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. *Mol. Psychiatry* **17**, 1272–1282
150. Martins, J. G., Bentsen, H., and Puri, B. K. (2012) Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. *Molec. Psychiatry* **17**, 1144–1149
151. Mischoulon, D. (2011) The impact of omega-3 fatty acids on depressive disorders and suicidality: can we reconcile 2 studies with seemingly contradictory results? *J. Clin. Psychiatry* **72**, 1574–1576
152. Günther, J., Schulte, K., Wenzel, D., Malinowska, B., and Schlicker, E. (2010) Prostaglandins of the E series inhibit monoamine release via EP3 receptors: proof with the competitive EP3 receptor antagonist L-826,266. *Naunyn Schmiedebergs Arch. Pharmacol.* **381**, 21–31
153. Schlicker, E., Fink, K., and Göthert, M. (1987) Influence of eicosanoids on serotonin release in the rat brain: inhibition by prostaglandins E1 and E2. *Naunyn Schmiedebergs Arch. Pharmacol.* **335**, 646–651
154. Rees, D., Miles, E. A., Banerjee, T., Wells, S. J., Roynette, C. E., Wahle, K. W., and Calder, P. C. (2006) Dose-related effects of eicosapentaenoic acid on innate immune function in healthy humans: a comparison of young and older men. *Am. J. Clin. Nutr.* **83**, 331–342
155. Vedin, I., Cederholm, T., Freund-Levi, Y., Basun, H., Hjorth, E., Irving, G. F., Eriksdotter-Jönhagen, M., Schultzberg, M., Wahlund, L. O., and Palmblad, J. (2010) Reduced prostaglandin F2 alpha release from blood mononuclear leukocytes after oral supplementation of omega3 fatty acids: the OmegAD study. *J. Lipid Res.* **51**, 1179–1185
156. Peet, M., and Horrobin, D. F.; E-E Multicentre Study Group. (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. *J. Psychiatr. Res.* **36**, 7–18
157. Hibbeln, J. R., Linnoila, M., Umhau, J. C., Rawlings, R., George, D. T., and Salem, N., Jr. (1998) Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. *Biol. Psychiatry* **44**, 235–242
158. US Department of Agriculture, ARS. (2014) *Nutrient Intakes from Food: Mean Amounts Consumed per Individual, by Gender and Age*, US Department of Agriculture, Washington, DC
159. Portanova, J. P., Zhang, Y., Anderson, G. D., Hauser, S. D., Masferrer, J. L., Seibert, K., Gregory, S. A., and Isakson, P. C. (1996) Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. *J. Exp. Med.* **184**, 883–891
160. Reichenberg, A., Yirmiya, R., Schuld, A., Kraus, T., Haack, M., Morag, A., and Pollmächer, T. (2001) Cytokine-associated emotional and cognitive disturbances in humans. *Arch. Gen. Psychiatry* **58**, 445–452
161. Su, K. P., Lai, H. C., Yang, H. T., Su, W. P., Peng, C. Y., Chang, J. P., Chang, H. C., and Pariante, C. M. (2014) Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. *Biol. Psychiatry* **76**, 559–566
162. Su, K. P., Huang, S. Y., Peng, C. Y., Lai, H. C., Huang, C. L., Chen, Y. C., Aitchison, K. J., and Pariante, C. M. (2010) Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. *Biol. Psychiatry* **67**, 550–557
163. Yehuda, S., Rabinovitz, S., and Mostofsky, D. I. (1999) Essential fatty acids are mediators of brain biochemistry and cognitive functions. *J. Neurosci. Res.* **56**, 565–570
164. Innis, S. M. (2007) Dietary (n-3) fatty acids and brain development. *J. Nutr.* **137**, 855–859
165. Georgieff, M. K., and Innis, S. M. (2005) Controversial nutrients that potentially affect preterm neurodevelopment: essential fatty acids and iron. *Pediatr. Res.* **57**, 99R–103R
166. Ahmad, A., Moriguchi, T., and Salem, N. (2002) Decrease in neuron size in docosahexaenoic acid-deficient brain. *Pediatr. Neurol.* **26**, 210–218
167. Bradbury, J. (2011) Docosahexaenoic acid (DHA): an ancient nutrient for the modern human brain. *Nutrients* **3**, 529–554
168. Calder, P. C. (2012) Mechanisms of action of (n-3) fatty acids. *J. Nutr.* **142**, 592S–599S
169. Salem, N., Jr., Litman, B., Kim, H. Y., and Gawrisch, K. (2001) Mechanisms of action of docosahexaenoic acid in the nervous system. *Lipids* **36**, 945–959
170. Wassall, S. R., and Stillwell, W. (2009) Polyunsaturated fatty acid-cholesterol interactions: domain formation in membranes. *Biochim. Biophys. Acta* **1788**, 24–32

171. Allen, J. A., Halverson-Tamboli, R. A., and Rasenick, M. M. (2007) Lipid raft microdomains and neurotransmitter signalling. *Nat. Rev. Neurosci.* **8**, 128–140
172. Escribá, P. V., Wedegaertner, P. B., Goñi, F. M., and Vögler, O. (2007) Lipid-protein interactions in GPCR-associated signaling. *Biochim. Biophys. Acta* **1768**, 836–852
173. Heron, D. S., Shinitzky, M., Hershkowitz, M., and Samuel, D. (1980) Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. *Proc. Natl. Acad. Sci. USA* **77**, 7463–7467
174. Paila, Y. D., Ganguly, S., and Chattopadhyay, A. (2010) Metabolic depletion of sphingolipids impairs ligand binding and signaling of human serotonin1A receptors. *Biochemistry* **49**, 2389–2397
175. Heinrichs, S. C. (2010) Dietary omega-3 fatty acid supplementation for optimizing neuronal structure and function. *Mol. Nutr. Food Res.* **54**, 447–456
176. Jones, C. R., Arai, T., and Rapoport, S. I. (1997) Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. *Neurochem. Res.* **22**, 663–670
177. Pinot, M., Vanni, S., Pagnotta, S., Lacas-Gervais, S., Payet, L. A., Ferreira, T., Gautier, R., Goud, B., Antonny, B., and Barelli, H. (2014) Lipid cell biology. Polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins. *Science* **345**, 693–697
178. Chalou, S. (2006) Omega-3 fatty acids and monoamine neurotransmission. *Prostaglandins Leukot. Essent. Fatty Acids* **75**, 259–269
179. de la Presa Owens, S., and Innis, S. M. (1999) Docosahexaenoic and arachidonic acid prevent a decrease in dopaminergic and serotonergic neurotransmitters in frontal cortex caused by a linoleic and alpha-linolenic acid deficient diet in formula-fed piglets. *J. Nutr.* **129**, 2088–2093
180. McNamara, R. K., Able, J., Liu, Y., Jandacek, R., Rider, T., Tso, P., and Lipton, J. W. (2009) Omega-3 fatty acid deficiency during perinatal development increases serotonin turnover in the prefrontal cortex and decreases midbrain tryptophan hydroxylase-2 expression in adult female rats: dissociation from estrogenic effects. *J. Psychiatr. Res.* **43**, 656–663
181. Chalou, S., Delion-Vancassel, S., Belzung, C., Guilloteau, D., Leguisquet, A. M., Besnard, J. C., and Durand, G. (1998) Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. *J. Nutr.* **128**, 2512–2519
182. Vancassel, S., Leman, S., Hanonick, L., Denis, S., Roger, J., Nollet, M., Bodard, S., Kousignian, I., Belzung, C., and Chalou, S. (2008) n-3 polyunsaturated fatty acid supplementation reverses stress-induced modifications on brain monoamine levels in mice. *J. Lipid Res.* **49**, 340–348
183. Levant, B. (2011) N-3 (omega-3) Fatty acids in postpartum depression: implications for prevention and treatment. *Depress. Res. Treat.* **2011**, 467349
184. Greenberg, J. A., Bell, S. J., and Ausdal, W. V. (2008) Omega-3 fatty acid supplementation during pregnancy. *Rev. Obstet. Gynecol.* **1**, 162–169
185. Bao, A. M., and Swaab, D. F. (2011) Sexual differentiation of the human brain: relation to gender identity, sexual orientation and neuropsychiatric disorders. *Front. Neuroendocrinol.* **32**, 214–226
186. Bao, A. M., and Swaab, D. F. (2010) Sex differences in the brain, behavior, and neuropsychiatric disorders. *Neuroscientist* **16**, 550–565
187. National Collaborating Centre for Mental Health. (2010) *Anti-social Personality Disorder: The Nice Guideline on Treatment, Management and Prevention*, The British Psychological Society and the Royal College of Psychiatrists, Leicester (UK)
188. National Collaborating Centre for Mental Health. (2006) *Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care*, The British Psychological Society and the Royal College of Psychiatrists, Leicester (UK)
189. Pecins-Thompson, M., Brown, N. A., Kohama, S. G., and Bethea, C. L. (1996) Ovarian steroid regulation of tryptophan hydroxylase mRNA expression in rhesus macaques. *J. Neurosci.* **16**, 7021–7029
190. Hiroi, R., McDevitt, R. A., and Neumaier, J. F. (2006) Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field. *Biol. Psychiatry* **60**, 288–295
191. Sanchez, R. L., Reddy, A. P., Centeno, M. L., Henderson, J. A., and Bethea, C. L. (2005) A second tryptophan hydroxylase isoform, TPH-2 mRNA, is increased by ovarian steroids in the raphe region of macaques. *Brain Res. Mol. Brain Res.* **135**, 194–203
192. Bethea, C. L., Mirkes, S. J., Shively, C. A., and Adams, M. R. (2000) Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. *Biol. Psychiatry* **47**, 562–576
193. Hiroi, R., McDevitt, R. A., Morcos, P. A., Clark, M. S., and Neumaier, J. F. (2011) Overexpression or knockdown of rat tryptophan hydroxylase-2 has opposing effects on anxiety behavior in an estrogen-dependent manner. *Neuroscience* **176**, 120–131
194. Carlsson, M., and Carlsson, A. (1988) In vivo evidence for a greater brain tryptophan hydroxylase capacity in female than in male rats. *Arch. Pharmacol.* **338**, 345–349
195. Carlsson, M., and Carlsson, A. (1988) A regional study of sex differences in rat brain serotonin. *Prog. Neuropsychopharmacol. Biol. Psychiatry* **12**, 53–61
196. Carlsson, M., Svensson, K., Eriksson, E., and Carlsson, A. (1985) Rat brain serotonin: biochemical and functional evidence for a sex difference. *J. Neural Transm.* **63**, 297–313
197. Renner, K. J., Biegon, A., and Luine, V. N. (1985) Sex differences in long-term gonadectomized rats: monoamine levels and [³H]nitroimipramine binding in brain nuclei. *Exper. Brain Res.* **58**, 198–201
198. Asberg, M., Bertilsson, L., Tuck, D., Cronholm, B., and Sjöqvist, F. (1973) Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. *Clin. Pharmacol. Ther.* **14**, 277–286
199. Sjöström, R., and Roos, B. E. (1972) 5-Hydroxyindolacetic acid and homovanillic acid in cerebrospinal fluid in manic-depressive psychosis. *Eur. J. Clin. Pharmacol.* **4**, 170–176
200. Epperson, C. N., Amin, Z., Ruparel, K., Gur, R., and Loughead, J. (2012) Interactive effects of estrogen and serotonin on brain activation during working memory and affective processing in menopausal women. *Psychoneuroendocrinology* **37**, 372–382
201. Amin, Z., Gueorguieva, R., Cappiello, A., Czarkowski, K. A., Stiklus, S., Anderson, G. M., Nafolin, F., and Epperson, C. N. (2006) Estradiol and tryptophan depletion interact to modulate cognition in menopausal women. *Neuropsychopharmacology* **31**, 2489–2497
202. Gogos, A., Nathan, P. J., Guille, V., Croft, R. J., and van den Buuse, M. (2006) Estrogen prevents 5-HT1A receptor-induced disruptions of prepulse inhibition in healthy women. *Neuropsychopharmacology* **31**, 885–889
203. Jovanovic, T., Szilagyi, S., Chakravorty, S., Fiallos, A. M., Lewison, B. J., Parwani, A., Schwartz, M. P., Gonzenbach, S., Rotrosen, J. P., and Duncan, E. J. (2004) Menstrual cycle phase effects on prepulse inhibition of acoustic startle. *Psychophysiology* **41**, 401–406
204. Gogos, A., and Van den Buuse, M. (2004) Estrogen and progesterone prevent disruption of prepulse inhibition by the serotonin-1A receptor agonist 8-hydroxy-2-dipropylaminotetralin. *J. Pharmacol. Exp. Ther.* **309**, 267–274
205. Bond, A. J., Wingrove, J., and Critchlow, D. G. (2001) Tryptophan depletion increases aggression in women during the premenstrual phase. *Psychopharmacology (Berl.)* **156**, 477–480
206. Sacher, J., Wilson, A. A., Houle, S., Rusjan, P., Hassan, S., Bloomfield, P. M., Stewart, D. E., and Meyer, J. H. (2010) Elevated brain monoamine oxidase A binding in the early postpartum period. *Arch. Gen. Psychiatry* **67**, 468–474
207. Dror, D. K., and Allen, L. H. (2010) Vitamin D inadequacy in pregnancy: biology, outcomes, and interventions. *Nutr. Rev.* **68**, 465–477
208. Baillara, K. M., Henry, C., Lestage, J., Launay, J. M., Parrot, F., Swendsen, J., Sutter, A. L., Roux, D., Dally, D., and Demotes-Mainard, J. (2006) Decreased brain tryptophan availability as a partial determinant of post-partum blues. *Psychoneuroendocrinology* **31**, 407–413
209. Sit, D., Rothschild, A. J., and Wisner, K. L. (2006) A review of postpartum psychosis. *J. Womens Health (Larchmt)* **15**, 352–368
210. Kelly, E., and Sharma, V. (2010) Diagnosis and treatment of postpartum bipolar depression. *Expert Rev. Neurother.* **10**, 1045–1051
211. Sharma, V., Khan, M., Corpse, C., and Sharma, P. (2008) Missed bipolarity and psychiatric comorbidity in women with postpartum depression. *Bipolar Disord.* **10**, 742–747

212. Kiank, C., Zeden, J. P., Drude, S., Domanska, G., Fusch, G., Otten, W., and Schuett, C. (2010) Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans. *PLoS ONE* **5**, e11825
213. Stevens, H. E., Su, T., Yanagawa, Y., and Vaccarino, F. M. (2013) Prenatal stress delays inhibitory neuron progenitor migration in the developing neocortex. *Psychoneuroendocrinology* **38**, 509–521
214. Miyagawa, K., Tsuji, M., Fujimori, K., Saito, Y., and Takeda, H. (2011) Prenatal stress induces anxiety-like behavior together with the disruption of central serotonin neurons in mice. *Neurosci. Res.* **70**, 111–117
215. Lukkes, J. L., Kopelman, J. M., Donner, N. C., Hale, M. W., and Lowry, C. A. (2013) Development × environment interactions control tph2 mRNA expression. *Neuroscience* **237**, 139–150
216. Turner, E. H., Loftis, J. M., and Blackwell, A. D. (2006) Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. *Pharmacol. Ther.* **109**, 325–338
217. Li, N., Ghia, J. E., Wang, H., McClemens, J., Cote, F., Suehiro, Y., Mallet, J., and Khan, W. I. (2011) Serotonin activates dendritic cell function in the context of gut inflammation. *Am. J. Pathol.* **178**, 662–671
218. Young, S. N. (2007) How to increase serotonin in the human brain without drugs. *J. Psychiatry Neurosci.* **32**, 394–399
219. American Psychiatric Association. (2013) *Diagnostic and Statistical Manual of Mental Disorders*, 5th Ed. American Psychiatric Publishing Washington, DC
220. Lakhan, S. E., and Vieira, K. F. (2008) Nutritional therapies for mental disorders. *Nutr. J.* **7**, 2
221. Fergusson, D., Doucette, S., Glass, K. C., Shapiro, S., Healy, D., Hebert, P., and Hutton, B. (2005) Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. *BMJ* **330**, 396
222. Mousain-Bosc, M., Roche, M., Polge, A., Pradal-Prat, D., Rapin, J., Bali, J. P. (2006) Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. I. Attention deficit hyperactivity disorders. *Magnesium Res.* **19**, 46–52
223. Kuriyama, S., Kamiyama, M., Watanabe, M., Tamahashi, S., Muraguchi, I., Watanabe, T., Hozawa, A., Ohkubo, T., Nishino, Y., Tsubono, Y., Tsuji, I., and Hisamichi, S. (2002) Pyridoxine treatment in a subgroup of children with pervasive developmental disorders. *Dev. Med. Child Neurol.* **44**, 284–286
224. McCann, J. C., and Ames, B. N. (2007) An overview of evidence for a causal relation between iron deficiency during development and deficits in cognitive or behavioral function. *Am. J. Clin. Nutr.* **85**, 931–945
225. Danaei, G., Ding, E. L., Mozaffarian, D., Taylor, B., Rehman, J., Murray, C. J., and Ezzati, M. (2009) The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. *PLoS Med.* **6**, e1000058
226. Shelton, D., Sampl, S., Kesten, K. L., Zhang, W., and Trestman, R. L. (2009) Treatment of impulsive aggression in correctional settings. *Behav. Sci. Law* **27**, 787–800
227. Jiang, P., Zhang, L. H., Cai, H. L., Li, H. D., Liu, Y. P., Tang, M. M., Dang, R. L., Zhu, W. Y., Xue, Y., and He, X. (2014) Neurochemical effects of chronic administration of calcitriol in rats. *Nutrients* **6**, 6048–6059

Received for publication December 15, 2014.

Accepted for publication February 4, 2015.